

COLLEGE OF PUBLIC HEALTH CURRICULUM VITAE

Elizabeth A. Chrischilles

April 7, 2020

I. EDUCATION AND PROFESSIONAL HISTORY

A. Education

<u>Institution</u>	<u>Field of Study</u>	<u>Degree Obtained</u>	<u>Degree Date</u>
University of Iowa College of Pharmacy, Iowa City, Iowa	Pharmacy	BS	1979
University of Iowa College of Pharmacy, Iowa City, Iowa	Pharmacy	MS	1981
The University of Iowa, Iowa City, Iowa, United States	Clinical Pharmacy	Fellow	1982
University of Iowa College of Pharmacy, Iowa City, Iowa	Pharmacy	PhD	1986

Certification/Licensure

<u>Board</u>	<u>Date</u>
Iowa Pharmacy Perm. #C-15469, Iowa Board of Pharmacy	1979 - Present

B. Professional and Academic Positions

<u>Position Title</u>	<u>Dates of Service</u>	<u>Location/Institution</u>
Clinical Pharmacy Faculty	1982-1984	Cedar Rapids Medical Education Program, Cedar Rapids
Clinical Pharmacist Manager	1982-1984	Pioneer Medical Center, Mechanicsville
Clinical Assistant Professor	1982-1984	Division of Clinical/Hospital Pharmacy, University of Iowa College of Pharmacy, Iowa City

<u>Position Title</u>	<u>Dates of Service</u>	<u>Location/Institution</u>
Visiting Assistant Professor	1986-1987	Department of Preventive Medicine, University of Iowa College of Medicine, Iowa City
Assistant Professor	1987-1994	Department of Preventive Medicine, University of Iowa College of Medicine, Iowa City
Associate Professor	1994-1999	Department of Preventive Medicine, University of Iowa College of Medicine, Iowa City
Associate Professor	1999-2000	Department of Epidemiology, University of Iowa College of Public Health, Iowa City
Professor	2000-Present	Department of Epidemiology, University of Iowa College of Public Health, Iowa City
Associate Head for Admissions and Curriculum	2000-2010	College of Public Health, Department of Epidemiology, University of Iowa, Iowa City
Professor	2000-Present	Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City
Associate Director for Population Sciences	2007-Present	Holden Comprehensive Cancer Center, Iowa City
Co-Director, BERD Key Function	2007-Present	Institute for Clinical and Translational Science, Iowa City
Professor (secondary appointment)	2009-2020	Institute for Clinical and Translational Science, Iowa City
Biomedical Informatics Core co-director	2016-Present	Institute for Clinical and Translational Science
Associate Director	2017-Present	Institute for Clinical and Translational Science, Iowa City
Department Head	2017-Present	Department of Epidemiology, University of Iowa

C. Honors, Awards, Recognitions, and Outstanding Achievements

<u>Year</u>	<u>Title</u>
-------------	--------------

<u>Year</u>	<u>Title</u>
1987	Burroughs Wellcome Scholar Award in Pharmacoepidemiology, 5 year career development award
1997	Iowa Pharmacists Association Appreciation Award, Iowa Pharmacists Association
2000	Collegiate Teaching Award, College of Public Health, University of Iowa
2004	Faculty Teaching Award, College of Public Health, University of Iowa
2005	Recipient of the Wiederholt Prize, American Pharmacists Association
2007	Distinguished Faculty Lecturer, College of Public Health, University of Iowa
2007	Marvin A. and Rose Lee Pomerantz Chair in Public Health, College of Public Health, University of Iowa
2009	Iowa Pharmacy Association Appreciation Award, Iowa Pharmacy Association
2014	CPH Research Award, The University of Iowa, College of Public Health
2015	Fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine, Drexel University College of Medicine
2018-Present	Fellow, American College of Epidemiology
2018	Distinguished Alumni Award, College of Pharmacy, The University of Iowa

II. SCHOLARSHIP

A. Publications or Creative Works

1. Peer-Reviewed Papers

1. Chrischilles EA, Helling DK, Rowland CR (1982). Model for cost-benefit analysis of clinical pharmacy in family practice. *Am J Hosp Pharm* 39(6):992-998. PMID: 6808837
2. Chrischilles EA, Helling DK, Rowland CR (1984). Clinical pharmacy services in family practice: cost-benefit analysis. I. Physician time and quality of care. *Drug Intell Clin Pharm* 18(4):333-341. PMID: 6425028
3. Chrischilles EA, Helling DK, Rowland CR (1984). Clinical pharmacy services in family practice: cost-benefit analysis. II. Referrals, appointment compliance, and costs. *Drug Intell Clin Pharm* 18(5):436-441. PMID: 6426919
4. Chrischilles EA, Helling DK, Rowland CR (1985). Cost-benefit analysis of clinical pharmacy services in three Iowa family practice offices. *J Clin Hosp Pharm*, 10:59-66.

5. Semla TP, Chrischilles EA, Helling DK, Lemke JH, Wallace RB, Drube GA (1986). The relationship of nonsteroidal anti-inflammatory drug use to tinnitus in an elderly population. *Drug Intell Clin Pharm*, 20:472.
6. Chrischilles EA, Helling DK, Booth BM, Lemke JH, Mustion AL (1988). Documentation and appropriateness of prescribing for Veterans Administration ambulatory care patients. *Am J Hosp Pharm*, 45:2345-2351.
7. Chrischilles EA, Helling DK, Aschoff CR (1989). The effect of clinical pharmacy services on quality of family practice physician prescribing and medication costs. *Drug Intell Clin Pharm*, 23:417-421.
8. Chrischilles EA, Lemke JH, Wallace RB, Drube GA (1990). Prevalence and characteristics of multiple analgesic drug use in an elderly study group. *J Am Geriatr Soc* 38(9):979-984. PMID: 2212451
9. Chrischilles EA, Butler CD, Davis CS, Wallace RB (1991). A model of lifetime osteoporosis impact. *Arch Intern Med* 151(10):2026-2032. PMID: 1929691
10. Levy SM, Baker KA, Chrischilles EA (1991). Medications with dental significance: usage in a nursing home population. *Spec Care Dent*, 11:19-25.
11. Semla TP, Lemke JH, Helling DK, Wallace RB, Chrischilles EA (1991). Perceived purpose of prescription drugs: the Iowa 65+ Rural Health Study. *DICP* 25(4):410-413. PMID: 1926912
12. Xakellis GC, Chrischilles EA (1992). Hydrocolloid versus saline-gauze dressings in treating pressure ulcers: a cost-effectiveness analysis. *Arch Phys Med Rehabil* 73(5):463-469. PMID: 1580775
13. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL (1992). Perspective. How many women have osteoporosis? *J Bone Miner Res* 7(9):1005-1010. PMID: 1414493
14. Chrischilles EA, Segar ET, Wallace RB (1992). Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. *Ann Intern Med* 117(8):634-640. PMID: 1530194
15. Chrischilles EA, Foley DJ, Wallace RB (1992). Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. *J Gerontol Med Sci* 47(5):M137-M144.
16. Chrischilles EA, Wallace RB (1993). Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. *J Gerontol:Med Sci*, 48:M91-M96.
17. Layfield LJ, Chrischilles EA, Cohen MB, Bottles K (1993). The palpable breast nodule. A cost-effectiveness analysis of alternate diagnostic approaches. *Cancer* 72(5):1642-1651. PMID: 8348496
18. Chrischilles EA, Shireman T, Wallace R (1994). Costs and health effects of osteoporotic fractures. *Bone* 15(4):377-386. PMID: 7917575

19. Pahor M, Guralnik JM, Salive ME, Chrischilles EA, Manto A, Wallace RB (1994). Disability and severe gastrointestinal hemorrhage. A prospective study of community-dwelling older persons. *JAGS*, 42:816-825.
20. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P (1994). Drug data coding and analysis in epidemiologic studies. *European J of Epidemiology*, 10:1-7.
21. Pahor M, Guralnik JM, Chrischilles EA, Wallace RB (1994). Use of laxative medication in older persons and associations with low serum albumin. *JAGS*, 42:50-56.
22. Saag KG, Rubenstein LM, Chrischilles EA, Wallace RB (1995). Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly. *J Rheumatology*, 22:11.
23. Lipton HL, Byrns PJ, Soumerai SB, Chrischilles EA (1995). Pharmacists as agents of change for rational drug therapy. *Int J Technol Assess Health Care* 11(3):485-508. PMID: 7591549
24. Glynn RJ, Brock DB, Harris T, Havlik RJ, Chrischilles EA, Ostfeld AM, Taylor JO, Hennekens CH (1995). Use of antihypertensive drugs and trends in blood pressure in the elderly. *Arch Intern Med* 155(17):1855-1860. PMID: 7677551
25. Chrischilles EA, Gondek K (1997). Do practice guidelines augment drug utilization review? *Pharmacoeconomics* 12(6):648-666. PMID: 10175977
26. Taylor TN, Chrischilles EA (1997). Economic evaluation of interventions in endocrinology. *Endocrinol Metab Clin North Am* 26(1):67-87. PMID: 9074853
27. Currie JD, Chrischilles EA, Kuehl AK, Buser RA (1997). Effect of a training program on community pharmacists' detection of and intervention in drug-related problems. *J Am Pharm Assoc*, 37:182-191.
28. Carter BL, Barnette DJ, Chrischilles EA, Mazzotti GJ, Asali ZJ (1997). Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. *Pharmacotherapy* 17(6):1274-1285. PMID: 9399611
29. Schwartz DA, Doebbeling BN, Merchant JA, The Iowa Persian Gulf Study Group (1997). Self-reported illness and health status among Gulf War veterans. *JAMA* 277(3):238-245.
30. Rubenstein LM, Chrischilles EA, Voelker MD (1997). The impact of Parkinson's disease on health status, health expenditures, and productivity: Estimates from the National Medical Expenditure Survey. *Pharmacoeconomics* 12(4):486-498.
31. Hoerger TJ, Bala MV, Rowland C, Greer M, Chrischilles EA, Holloway RG (1998). Cost effectiveness of pramipexole in Parkinson's disease in the US. *Pharmacoeconomics* 14(5):541-557. PMID: 10344917
32. Kuehl AK, Chrischilles EA, Sorofman BA (1998). System for exchanging information among pharmacists in different practice environments. *Consult Pharm*, 5:564-574.
33. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL (1998). The health burdens of Parkinson's disease. *Movement Disorders* 13(3):406-413.

34. Phillips CR, Bjornson DC, Chrischilles EA, Sorofman B, Larson L (1998). The pharmacist's assessment of second generation on-line prospective drug utilization review. *J Man Care Pharm*, 4:183-191.
35. Rubenstein LM, Voelker MD, Chrischilles EA (1998). The usefulness of the functional status questionnaire and the medical outcomes study short form (SF-36) in Parkinson's disease research. *Quality of Life Research*, 7:279-290.
36. Chrischilles EA, Scholz DA (1999). Dollars and Sense: A practical guide to cost analysis for hospital epidemiology and infection control. *Clinical Performance and Quality Health Care* 7(2):107-111.
37. Armstrong EP, Chrischilles EA (2000). Electronic prescribing and monitoring are needed to improve drug use. *Archives of Internal Medicine* 160(18):2713-2716.
38. Brooks JM, Chrischilles EA, Scott S, Ritho J, Chen-Hardee S (2000). Information gained from linking SEER Cancer Registry Data to state-level hospital discharge abstracts. Surveillance, Epidemiology, and End Results. *Med Care* 38(11):1131-1140. PMID: 11078053
39. Rubenstein LM, DeLeo A, Chrischilles EA (2001). Economic and health-related quality of life considerations of new therapies in Parkinson's disease. *Pharmacoeconomics* 19(7):729-752. PMID: 11548910
40. Chrischilles EA, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H (2001). Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. *Clin Ther* 23(5):727-743. PMID: 11394731
41. Wakefield B, Blegen M, Uden-Holman TM, Vaughn TE, Chrischilles EA, Wakefield D (2001). Organizational culture, continuous quality improvement and medication administration error reporting. *American Journal of Medical Quality* 16(4):128-134.
42. Merlino LA, Bagchi I, Taylor TN, Utrie P, Chrischilles EA, Sumner W, Mudano A, Saag KG (2001). Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. *Med Decis Making* 21(2):122-132. PMID: 11310945
43. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM (2001). The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. *Osteoporos Int* 12(8):654-660. PMID: 11580079
44. Chrischilles EA, Gilden D, Kubisiak J, Rubenstein L, Shah H (2002). Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. *Am J Manag Care* 8(10):902-911. PMID: 12395958
45. Voelker MD, Saag KG, Schwartz DA, Chrischilles EA, Clarke WR, Woolson RF, Doebbeling BN (2002). Health-related quality of life in Gulf War era military personnel. *Am J Epidemiol*, 155:899-907.
46. Chrischilles EA, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB (2002). Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. *Cancer Control* 9(3):203-211. PMID: 12060818

47. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL (2002). Linking clinical variables to health-related quality of life in Parkinson's disease *Parkinsonism Relat Disord* 8(3):199-209. PMID: 12039432
48. Carter BL, Lund BC, Hayase N, Chrischilles EA (2002). The extent of potential antihypertensive drug interactions in a Medicaid population. *Am J Hypertens* 15(11):953-957. PMID: 12441214
49. Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA (2002). The role of pharmacy computer systems in preventing medication errors. *J Am Pharm Assoc (Wash)* 42(3):439-448. PMID: 12030631
50. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS (2003). Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. *J Manag Care Pharm* 9(2 Suppl):15-21. PMID: 14613340
51. Lund BC, Chrischilles EA, Carter BL, Ernst ME, Perry PJ (2003). Development of a computer algorithm for defining an active drug list using an automated pharmacy database. *J Clin Epidemiol* 56(8):802-806. PMID: 12954474
52. Carter BL, Chrischilles EA, Scholz D, Hayase N, Bell N (2003). Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program. *J Am Pharm Assoc (Wash)* 43(1):24-33. PMID: 12585748
53. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M (2003). Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. *Cancer Control* 10(5):396-403. PMID: 14581895
54. Nygaard I, Turvey C, Burns TL, Chrischilles EA, Wallace RB (2003). Urinary incontinence and depression in middle-aged United States women. *Obstet Gynecol* 101(1):149-156.
55. Brooks JM, Chrischilles EA, Scott SD, Chen-Hardee SS (2003). Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa. *Health Serv Res* 38(6 Pt 1):1385-1402. PMID: 14727779
56. Carter BL, Lund BC, Hayase N, Chrischilles EA (2004). A longitudinal analysis of antihypertensive drug interactions in a Medicaid population. *Am J Hypertens* 17(5 Pt 1):421-427. PMID: 15110901
57. Chrischilles EA, Ahrens R, Kuehl A, Kelly K, Thorne P, Burmeister LF, Merchant JA (2004). Asthma prevalence and morbidity among rural Iowa schoolchildren. *Journal of Allergy and Clinical Immunology* 113(1):66-71.
58. Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA (2004). Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. *JMCP* 10(5):412-422.

59. Chrischilles EA, Carter BL, Lund BC, Rubenstein LM, Chen-Hardee SS, Voelker MD, Park TR, Kuehl AK (2004). Evaluation of the Iowa Medicaid pharmaceutical case management program. *J Am Pharm Assoc* (2003) 44(3):337-349. PMID: 15191244
60. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA (2004). The concurrent use of anticholinergics and cholinesterase inhibitors: Rare event or common practice? *JAGS* 52(12):2082-2087.
61. Davila JA, Brooks JM, Pendergast JF, Chrischilles EA (2004). The effect of physician characteristics and their practice environment on surgical referral patterns for early-stage breast cancer in Iowa. *American Journal of Medical Quality* 19(6):266-273.
62. Ayanian JZ, Chrischilles EA, Wallace RB, Fletcher RH, Fouad MN, Kiefe CI, Harrington DP, Weeks JC, Kahn KL, Malin JL, Lipscomb J, Potosky AL, Provenzale DT, Sandler RS, van Ryn M, West DW (2004). Understanding cancer treatment and outcomes: The cancer care outcomes research and surveillance consortium. *Journal of Clinical Oncology* 22(15):2992-2996.
63. Merchant JA, Naleway AL, Svendsen ER, Kelly KM, Burmeister LF, Stromquist AM, Taylor CD, Thorne PS, Reynolds SJ, Sanderson WT, Chrischilles EA (2005). Asthma and farm exposures in a cohort of rural Iowa children. *Environmental Health Perspectives* 113(3):350-356.
64. Chrischilles EA, Klepser DG, Brooks JM, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ (2005). Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. *Pharmacotherapy* 25(5):668-675.
65. Durairaj L, Torner JC, Chrischilles EA, Sarrazin MV, Yankey J, Rosenthal GE (2005). Hospital volume-outcome relationships among medical admissions to ICUs. *Chest* 128(3):1682-1689.
66. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL (2005). How many women have osteoporosis? *Journal of Bone & Mineral Research* 20(5):886-892.
67. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles EA, Link BK (2005). Improved survival of follicular lymphoma patients in the United States. *Journal of Clinical Oncology* 23(22):5019-5026.
68. Eggleston PA, Diette G, Lipsett M, Lewis T, Tager I, McConnell R, Chrischilles EA, Lanphear B, Miller R, Krishnan J (2005). Lessons learned for the study of childhood asthma from the centers for children's environmental health and disease prevention research. *Environ Health Perspect* 113(10):1430-1436. PMID: 16203259
69. Brooks JM, Irwin CP, Hunsicker LG, Flanigan MJ, Chrischilles EA, Pendergast JF (2006). Effect of dialysis center profit-status on patient survival: A comparison of risk-adjustment and instrumental variable approaches. *Health Services Research* 41(6):2267-2289.
70. Wilson RT, Chase GA, Chrischilles EA, Wallace RB (2006). Hip fracture risk among community-dwelling elderly people in the United States: A prospective study of physical, cognitive, and socioeconomic indicators. *Am J Public Health* 96(7):1210-1218.

71. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA (2006). Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. *Acta Psychiatrica Scandinavica* 113(2):135-141.
72. Chen-Hardee S, Chrischilles EA, Voelker MD (2006). Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma. *Cancer Causes & Control* 17(5):647-754.
73. Wolinsky F, Miller TR, Geweke JF, Chrischilles EA, An H, Wallace RB, Pavlik CE, Wright KB, Ohsfeldt RL, Rosenthal GE (2007). An interpersonal continuity of care measure for Medicare part B claims analyses. *J Gerontol B Psychol Sci Soc Sci* 62(3):S160-S168.
74. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA, Flaum M (2007). Antipsychotic polytherapy in a state Medicaid program from 1990 to 2001. *The Journal of the College of Psychiatric and Neurologic Pharmacists* available at: http://cpnp.org/_docs/resource/jcpnp/state-medicaid-1990-2001.pdf.
75. Heederik D, Sigsgaard T, Thorne PS, Kline JN, Avery R, Bonlokke JH, Chrischilles EA, Dosman JA, Duchaine C, Kirkhorn SR, Kulhankova K, Merchant JA (2007). Health effects of airborne exposures from concentrated animal feeding operations. *Environ Health Perspect* 115(2):298-302.
76. Brooks JM, Chrischilles EA (2007). Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods. *Med Care* 45(10 Suppl 2):S123-S130. PMID: 17909370
77. Wolinsky F, Miller TR, An H, Geweke JF, Wallace RB, Wright KB, Chrischilles EA, Liu L, Pavlik CB, Cook EA, Ohsfeldt RL, Richardson KK, Rosenthal GE (2007). Hospital episodes and physician visits the concordance between self-reports and Medicare claims. *Med Care* 45(4):300-307.
78. Chrischilles EA, Rubenstein L, VanGilder R, Voelker M, Wright K, Wallace RB (2007). Risk factors for adverse drug events among older adults with mobility limitations in the community setting. *JAGS* 55(1):29-34.
79. Wolinsky F, Liu L, Miller TR, Geweke JF, Cook EA, Greene BR, Wright KB, Chrischilles EA, Pavlik CE, An H, Ohsfeldt RL, Richardson KK, Rosenthal GE, Wallace RB (2007). The use of chiropractors by older adults in the United States. *Chiropractic & Osteopathy*, 15:12.
80. Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, Hartz AJ (2008). A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. *Journal of Clinical Hypertension (Greenwich)* 10(4):260-271. PMC: 2453045, PMID: 18401223
81. Carnahan RM, Lund BC, Chrischilles EA, Perry PJ (2008). Consistency of antidepressant and chronic nonpsychiatric medication use in a high risk clinical population. *Research in Social and Administrative Pharmacy* 4(4):367-374. PMID: 19064243
82. Wolinsky F, Liu L, Miller TR, An H, Geweke JF, Kaskie B, Wright KB, Chrischilles EA, Pavlik CE, Cook EA, Ohsfeldt RL, Richardson KK, Rosenthal GE, Wallace RB (2008).

Emergency department utilization patterns among older adults. *Journal of Gerontology: Medical Sciences* 63A(2):204-209. PMC: 2923576, PMID: 18314459

83. Park TR, Brooks JM, Chrischilles EA, Bergus G (2008). Estimating the effect of treatment rate changes when treatment benefits are heterogeneous: antibiotics and otitis media. *Value Health* 11(2):304-314. PMID: 18380643
84. Zhao Y, Brooks JM, Flanigan MJ, Chrischilles EA, Pendergast JF, Hunsicker LG (2008). Physician access and early nephrology care in elderly patients with end-stage renal disease. *Kidney Int* 74(12):1596-1602. PMID: 18509317
85. Wolinsky F, Bentler SE, Cook EA, Chrischilles EA, Liu L, Wright KB, Geweke JF, Obrizan M, Pavlik CE, Ohsfeldt RL, Jones MP, Wallace RB, Rosenthal GE (2009). A 12-year prospective study of stroke risk in older Medicare beneficiaries. *BMC Geriatrics*, 9:17. PMC: 2683849, PMID: 19426528
86. Chrischilles EA, VanGilder R, Wright K, Kelly M, Wallace RB (2009). Inappropriate medication use as a risk factor for self-reported adverse drug effects in older adults. *JAGS* 57(6):1000-1006. PMID: 19507293
87. Lee SS, Schwemm AK, Reist J, Cantrell M, Andreski M, Doucette WR, Chrischilles EA, Farris KB (2009). Pharmacists' and pharmacy students' ability to identify drug-related problems using TIMER (Tool to Improve Medications in the Elderly via Review). *Am J Pharm Educ* 73(3):52. PMID: 19564995
88. Carter BL, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, Chrischilles EA, Franciscus CL, Xu Y (2009). Physician/pharmacist collaboration to improve blood pressure control. *Archives of Internal Medicine* 169(21):1996-2002. PMC: 2882170, PMID: 19933962
89. Wolinsky F, Bentler SE, Liu L, Obrizan M, Cook EA, Wright KB, Geweke JF, Chrischilles EA, Pavlik CE, Ohsfeldt RL, Jones MP, Richardson KK, Rosenthal GE, Wallace RB (2009). Recent hospitalization and the risk of hip fracture among older Americans. *J Gerontol A Biol Sci Med Sci* 64(2):249-255. PMC: 2655029, PMID: 19196641
90. Bentler SE, Obrizan M, Cook EA, Wright KB, Geweke JF, Chrischilles EA, Pavlik CE, Wallace RB, Ohsfeldt RL, Jones MP, Rosenthal GE, Wolinsky F (2009). The aftermath of hip fracture: Discharge placement, functional status change and mortality. *American Journal of Epidemiology* 170(10):1290-1299. PMC: 2781759, PMID: 19808632
91. Carter BL, Clarke W, Ardery G, Weber CA, James PA, Vander Weg M, Chrischilles EA, Vaughn T, Egan BM, Collaboration Among Pharmacists Physicians To Improve Outcomes Now (CAPTION) Trial Investigators (2010). A cluster-randomized effectiveness trial of a physician-pharmacist collaborative model to improve blood pressure control. *Circ Cardiovasc Qual Outcomes* 3(4):418-423. PMC: 2931811, PMID: 20647575
92. Fang G, Brooks JM, Chrischilles EA (2010). A new method to isolate local-area practice styles in prescription use as the basis for instrumental variables in comparative effectiveness research. *Med Care*, 48:710-717. PMID: 20613655
93. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH (2010). Adjuvant chemotherapy use

and adverse events among older patients with stage III colon cancer. *JAMA* 303(11):1037-1045. PMID: 20233821

94. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar Y, Fletcher RH (2010). Adverse events among the elderly receiving chemotherapy for advanced non-small cell lung cancer: A report from the cancer care outcomes research surveillance consortium (CanCORS). *JCO* 28(4):620-627. PMC: 2815997, PMID: 20038726
95. Wolinsky F, Bentler SE, Liu L, Geweke JF, Cook EA, Obrizan M, Chrischilles EA, Wright KB, Jones MP, Rosenthal GE, Ohsfeldt RL, Wallace RB (2010). Continuity of care with a primary care physician and mortality in older adults. *J Gerontol A Biol Sci Med Sci* 65(4):421-428. PMC: 2844057, PMID: 19995831
96. Kaskie B, Orbizan M, Cook EA, Jones MP, Liu L, Bentler S, Wallace RB, Geweke JF, Wright KB, Chrischilles EA, Pavlik CE, Ohsfeldt RL, Rosenthal GE, Wolinsky F (2010). Defining emergency department episodes by severity and intensity: A 15-year study of Medicare beneficiaries. *MBC Health Serv Res* 10(1):173. PMC: 2903585, PMID: 20565949
97. Carter BL, Doucette WR, Franciscus CL, Ardery G, Kluesner KM, Chrischilles EA (2010). Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. *Pharmacotherapy* 30(3):228-235. PMID: 20180606
98. Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ (2010). Inappropriate prescribing predicts adverse drug events in older adults. *Ann Pharmacother* 44(6):957-963. PMID: 20460558
99. Wolinsky F, Bentler SE, Liu L, Jones MP, Kaskie B, Hockenberry J, Chrischilles EA, Wright KB, Geweke JF, Obrizan M, Ohsfeldt RL, Rosenthal GE, Wallace RB (2010). Prior hospitalization and the risk of heart attack in older adults: A 12-year prospective study of Medicare beneficiaries. *Journal of Gerontology: Medical Sciences* 65(7):769-777. PMC: 2904597, PMID: 20106961
100. Lund BC, Steinman MA, Chrischilles EA, Kaboli PJ (2011). Beers criteria as a proxy for inappropriate prescribing of other medications among older adults. *Ann Pharmacother*, 45:1363-1370. PMC: 3906722, PMID: 21972251
101. McDowell BD, Wallace RB, Carnahan RM, Chrischilles EA, Lynch CF, Schlechte JA (2011). Demographic differences in incidence for pituitary adenoma. *Pituitary* 14(1):23-30. PMC: 3652258, PMID: 20809113
102. Hourcade JP, Chrischilles EA, Gryzlak BM, Hanson BM, Dunbar DE, Eichmann DA, Lorentzen RR (2011). Design lessons for older adult personal health records software from older adults. *Proceedings of 6th International Conference on Universal Access in Human-Computer Interaction, held as part of HCI International. Lecture Notes in Computer Science*, 6766:176-185.
103. Link BK, Brooks J, Wright K, Pan X, Voelker M, Chrischilles E (2011). Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. *Leuk Lymphoma* 52(6):994-1002. PMC: 3601377, PMID: 21338277

104. Prabhakar M, Haynes WG, Coryell WH, Chrischilles EA, Miller de, Arndt S, Ellingrod VL, Warren L, Fiedorowicz JG (2011). Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. *Pharmacotherapy* 31(8):806-812. PMID: 21923607
105. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM (2011). Incidence of and risk factors for community-associated *Clostridium difficile* infection: a nested case-control study. *BMC Infect Dis*, 11:194. PMID: 21762504
106. Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R (2011). Outcomes following local therapy for early-stage breast cancer in non-trial populations. *Breast Cancer Res Treat* 125(3):803-813. PMID: 20376555
107. Potosky AL, Malin JL, Kim B, Chrischilles EA, Weeks JC (2011). Re: Personalized medicine and cancer supportive care: Appropriate use of colony-stimulating factor support of chemotherapy. *J Natl Cancer Inst* 103(24):1899-1901. PMC: 3243676, PMID: 22036767
108. Wentzlaff DM, Carter BL, Ardery G, Franciscus CL, Doucette WR, Chrischilles EA, Rosenkrans KA, Buys LM (2011). Sustained Blood pressure control following discontinuation of a pharmacist intervention. *J Clin Hypertens* 13(6):431-437. PMID: 21649843
109. Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC (2011). Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. *J Natl Cancer Inst* 103(12):979-982. PMID: 21670423
110. Fang G, Brooks JM, Chrischilles EA (2012). Apples and oranges? Interpretations of risk adjustment and instrumental variable estimates of intended treatment effects using observational data. *American Journal of Epidemiology* 175(1):60-65. PMID: 22085626
111. Fang G, Brooks JM, Chrischilles EA (2012). Comparison of instrumental variable analysis using a new instrument with risk adjustment methods to reduce confounding by indication. *Am J Epidemiol* 175(11):1142-1151. PMID: 22510277
112. Patterson BJ, Doucette WR, Lindgren SD, Chrischilles EA (2012). Living with disability: Patterns of health problems and symptom mediation of health consequences. *Disabil Health J* 5(3):151-8. PMID: 22726855
113. Cook EA, Farris KB, Chrischilles EA, Aquilino M (2012). Relationship between availability of contraceptive products and pharmacists as information sources. *J Am Pharm Assoc* 52(3):342-348. PMID: 22618974
114. Brooks JM, Chrischilles EA, Landrum MB, Wright KB, Gang F, Weiner EP, Keating NL (2012). Survival implications associated with variation in mastectomy rates for early-staged breast cancer. *International Journal of Surgical Oncology*, 2012:Article ID 127854, 1-9. PMC: 3423912, PMID: 22928097
115. Platt R, Carnahan RM, Brown JS, Chrischilles EA, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, Toh S, Weiner MG (2012). The U.S. Food and Drug Administration's mini-sentinel program: status and direction. *Pharmacoepidemiol Drug Saf*, Suppl 1:1-8. PMID: 22262586

116. Cook EA, Schneider KM, Chrischilles E, Brooks JM (2013). Accounting for unobservable exposure time bias when using Medicare prescription drug data. *Medicare & Medicaid Research Review* 3(4):E1-E18.
117. Smith HL, Chrischilles E, Janus TJ, Sidwell RA, Ramirez M, Peek-Asa C, Sahr SM (2013). Clinical indicators of midface fracture in patients with trauma. *Dent Traumatol* 29(4):313-8. PMID: 23067335
118. Shiyanbola OO, Farris KB, Chrischilles E (2013). Concern beliefs in medications: Changes over time and medication use factors related to a change in beliefs. *Res Social Adm Pharm* 9(4):446-57. PMID: 22999805
119. Doucette WR, Chang EH, Pendergast JF, Wright KB, Chrischilles EA, Farris KB (2013). Development and initial assessment of the medication user self-evaluation (MUSE) tool. *Clin Ther* 35(3):344-50. PMID: 23453405
120. Charlton ME, Lin C, Jiang D, Stitzenberg KB, Halfdanarson TR, Pendergast JF, Chrischilles EA, Wallace RB (2013). Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. *Am J Clin Oncol* 36(6):572-9. PMC: 3556239, PMID: 2299264
121. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D (2013). Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: A cancer care outcomes research and surveillance consortium (CanCORS) Study. *J Clin Oncol* 31(5):558-64. PMC: 3565181, PMID: 23295799
122. Baker M, Nguyen M, Mullersman J, Lauer J, Zinderman C, Riedlinger K, Nakasato C, Chrischilles E, Garcia C, Balsbaugh C, Vajani M (2013). PS3-6: Blood safety continuous active-surveillance network feasibility evaluation (Blood-SCAN). *Clin Med Res* 11(3):169. PMC: 3788538, PMID: 24086005
123. O'Donnell BE, Schneider KM, Brooks JM, Lessman G, Wilwert J, Cook E, Martens G, Wright K, Chrischilles EA (2013). Standardizing medicare payment information to support examining geographic variation in costs. *Medicare & Medicaid Research Review* 3(3):E1-21.
124. Carter BL, Coffey CS, Uribe L, James PA, Egan BM, Ardery G, Chrischilles EA, Ecklund D, VanderWeg M, Vaughn T, Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) trial investigators (2013). Similar blood pressure values across racial and economic groups: baseline data from a group randomized clinical trial. *J Clin Hypertens (Greenwich)* 15(6):404-12. PMC: 3683891, PMID: 23730989
125. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D (2013). Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. *J Clin Oncol* 31(21):2730-5. PMC: 3709058, PMID: 23775958
126. Brooks JM, Tang Y, Chapman CG, Cook EA, Chrischilles EA (2013). What is the effect of area size when using local area practice style as an instrument? *J Clin Epidemiol* 66(8 suppl):S69-83. PMC: 3718893, PMID: 23849157
127. Doucette WR, Zhang Y, Chrischilles EA, Pendergast JF, Newland BA, Farris KB, Frank J (2013). Factors affecting Medicare Part D beneficiaries' decision to receive comprehensive medication reviews. *J Am Pharm Assoc* 53(5):482-7. PMID: 24030125

128. Moga D, Carnahan RM, Lund BC, Pendergast JF, Wallace RB, Torner JC, Yue L, Chrischilles EA (2013). Risks and benefits of bladder antimuscarinics among elderly residents of veterans affairs community living centers. *J Am Med Dir Assoc* 14(10):749-60. PMID: 23639715
129. Chrischilles E, Schneider K, Wilwert J, Lessman G, O'Donnell B, Gryzlak B, Wright K, Wallace R (2014). Beyond comorbidity: Expanding the definition and measurement of complexity among older adults using administrative claims data. *Medical Care*, 52:Suppl 3:S75-84. PMID: 24561763
130. Vaughan-Sarrazin MS, Jones M, Mazur Z, Chrischilles E, Cram P (2014). Bleeding rates in Veterans Affairs in patients with atrial fibrillation who switch from warfarin to dabigatran. *Am J Med*, 127 (12):1179-1185. PMID: 25107386
131. Cook EA, Schneider KM, Robinson J, Wilwert J, Chrischilles E, Pendergast J, Brooks J (2014). Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates. *BMC Health Serv Res*, 14 (1):391. PMC: 4169833, PMID: 25223597
132. Vaughan-Sarrazin MS, Mazur A, Chrischilles E, Cram P (2014). Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. *Am Heart J* 168(1):53-39.e1. PMID: 24952860
133. Carter BL, Chrischilles EA, Rosenthal G, Gryzlak BM, Eisenstein EL, Vander Weg MW (2014). Efficacy and safety of nighttime dosing of antihypertensives: Review of the literature and design of a pragmatic clinical trial. *J Clin Hypertens (Greenwich)* 16(2):115-21. PMID: 24373519
134. Chrischilles EA, Doucette W, Farris K, Lindgren S, Gryzlak B, Rubenstein L, Youland K, Wallace RB (2014). Medication therapy management and complex patients with disability: A randomized controlled trial. *Annals of Pharmacotherapy* 48(2):158-67. PMID: 24259652
135. Brooks JM, Cook EA, Chapman CG, Kulchaitanaroaj P, Chrischilles EA, Welch S, Robinson J (2014). Geographic variation in statin use for complex acute myocardial infarction patients: evidence of effective care? *Med Care*, 52:Suppl 3:S37-44. PMID: 24561757
136. Chrischilles EA, Hourcade JP, Doucette W, Eichmann D, Gryzlak B, Lorentzen R, Wright K, Letuchy E, Mueller M, Farris K, Levy B (2014). Personal health records: a randomized trial of effects on elder medication safety. *Journal of the American Medical Informatics Association* 21(4):679-686. PMID: 24326536
137. McDanel JS, Ward MA, Leder L, Schweizer ML, Dawson JD, Diekema DJ, Smith TC, Chrischilles EA, Perencevich EN, Herwaldt LA (2014). Methicillin-resistant *Staphylococcus aureus* prevention practices in hospitals throughout a rural state. *Am J Infect Control* 42(8):868-73. PMID: 25087139
138. Carter BL, Coffey CS, Ardery G, Uribe L, Ecklund D, James P, Egan B, Vander Weg M, Chrischilles E, Vaughn T (2015). Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. *Circ Cardiovasc Qual Outcomes*, 8 (3):235-243. PMID: 25805647
139. Albertson J, McDanel JS, Carnahan R, Chrischilles E, Perencevich EN, Goto M, Jiang L, Alexander B, Schweizer ML (2015). Determination of risk factors for recurrent

methicillin-resistant staphylococcus aureus bacteremia in a Veterans Affairs healthcare system population. *Infect Control Hosp Epidemiol*, 36 (5):543-549. PMID: 25682861

140. Brooks JM, Cook E, Chapman CG, Schroeder MC, Chrischilles EA, Schneider KM, Kulchaitanaroaj P, Robinson J (2015). Statin use after acute myocardial infarction by patient complexity: Are the rates right? *Medical Care*, 53 (4):324-331. PMID: 25719431
141. Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E (2015). Treatment of diffuse large B-cell lymphoma (DLBCL) in the elderly: Regimens without anthracyclines are common and not futile. *Leuk Lymphoma* 56(1):65-71. PMID: 24625326
142. McDanel JS, Perencevich EN, Diekema DJ, Winokur PL, Johnson JK, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Schweizer ML (2015). Association between microbial characteristics and poor outcomes among patients with methicillin-resistant *Staphylococcus aureus* pneumonia: a retrospective cohort study. *Antimicrob Resist Infect Control*, 4:51. PMC: 4677450, PMID: 26668737
143. Schroeder MC, Lynch CF, Abu-Hejleh T, Chrischilles EA, Thomas A (2015). Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012. *Clinical Breast Cancer*, 15(1):e27-34. PMC: PMC4289459, PMID: 25245424
144. Kulchaitanaroaj P, Carter BL, Goedken AM, Chrischilles EA, Brooks JM (2015). Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs *Res Social Adm Pharm* 11(2):e69-83. PMID: 25155998
145. McDowell BD, Chapman CG, Smith BJ, Button AM, Chrischilles EA, Mezhir JJ (2015). Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: Results of an instrumental variable analysis. *Ann Surg* 261(4):740-745. PMC: 4277740, PMID: 24979599
146. Doucette WR, Pendergast JF, Zhang Y, Brown G, Chrischilles EA, Farris KB, Frank J (2015). Stimulating comprehensive medication reviews among Medicare Part D beneficiaries. *Am J Manag Care*, 21(6):e372-8. PMID: 26247578
147. Chrischilles EA, McDowell BD, Rubenstein L, Charlton M, Pendergast J, Juarez GY, Arora NK (2015). Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: The CanCORS disease-free survivor follow-up study. *J Cancer Surviv*, 9 (2):269-278. PMID: 25354481
148. Carter BL, Coffey CS, Chrischilles EA, Ardery G, Ecklund D, Gryzlak B, Vander Weg MW, James PA, Christensen AJ, Parker CP, Gums T, Finkelstein RJ, Uribe L, Polgreen LA, MEDication focused outpatient care for underutilization of secondary prevention (MEDFOCUS) trial investigators (2015). A cluster-randomized trial of a centralized clinical pharmacy cardiovascular risk service to improve guideline adherence. *Pharmacotherapy*, 35(7):653-62. PMID: 26111939
149. Carter BL, Levy BT, Gryzlak B, Chrischilles EA, Vander Weg MW, Christensen AJ, James PA, Moss CA, Parker CP, Gums T, Finkelstein RJ, Xu Y, Dawson JD, Polgreen LA (2015). A centralized cardiovascular risk service to improve guideline adherence in private primary care offices. *Contemporary Clinical Trials*, 43:25-32. PMC: PMC4522340, PMID: 25952471

150. Charlton ME, Stitzenberg KB, Lin C, Schlichting JA, Halfdanarson TR, Juarez GY, Pendergast JF, Chrischilles EA, Wallace RB (2015). Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. *Journal of Oncology Practice / American Society of Clinical Oncology*, 11(4):e476-86. PMC: PMC4507395, PMID: 26080831
151. McDanel JS, Perencevich EN, Diekema DJ, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Jiang L, Goto M, Schweizer ML (2015). Comparative Effectiveness of Beta-lactams versus Vancomycin for Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections among 122 Hospitals. *Clin Infect Dis*, 61 (3):361-367. PMID: 25900170
152. Lund BC, Carrel M, Gellad W, Chrischilles EE, Kaboli PJ (2015). Incidence- versus prevalence-based measures of inappropriate prescribing in the Veterans Health Administration. *J Am Geriatr Soc*, 63(8):1601-7. PMID: 26200069
153. Polgreen LA, Han J, Carter BL, Ardery GP, Coffey CS, Chrischilles EA, James PA, (2015). Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. *Hypertension*, 66(6):1145-51. PMC: 4644092, PMID: 26527048
154. Wright AA, Keating NL, Ayanian JZ, Chrischilles EA, Kahn KL, Ritchie CS, Weeks CJ, Earle CC, Landrum MB (2016). Family perspectives on aggressive cancer care near the end of Life. *JAMA*, 315(3):1-10.
155. Ammann EM, Jones MP, Link BK, Carnahan RM, Winiecki SK, Torner JC, McDowell BD, Fireman BH, Chrischilles EA (2016). Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. *Blood*, 127(2):200-207. PMC: 4713161, PMID: 26443622
156. Chrischilles EA, Schneider KM, Schroeder MC, Letuchy E, Wallace RB, Robinson JG, Brooks JM (2016). Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction. *Journal of the American Geriatrics Society*, 64(3):526-35. PMID: 26928940
157. Farris KB, Salgado TM, Aneese N, Marshall VD, Pendergast JF, Frank J, Chrischilles EA, Doucette WR (2016). Effect of clinical and attitudinal characteristics on obtaining comprehensive medication reviews. *J Manag Care Spec Pharm*, 22(4):388-95.
158. Abu-Hejleh T, Chrischilles EA, Halfdanarson TR, Simon C, Pendergast JF, Jiang D, Smith CJ, Porter AT, Carter KD, Wallace RB, Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) (2016). The effect of receiving treatment within a clinical trial setting on survival and quality of care perception in advanced stage non-small cell lung cancer. *Am J Clin Oncol* 39(2):126-31. PMID: 24632817
159. Thomas A, Khan SA, Chrischilles EA, Schroeder MC (2016). Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011. *JAMA Surg*, 151(5):424-31. PMID: 26629881
160. Ammann EM, Haskins CB, Fillman KM, Ritter RL, Gu X, Winiecki SK, Carnahan RM, Torner JC, Fireman BH, Jones MP, Chrischilles EA (2016). Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs. *Am J Hematol*, 91(6):594-605. PMID: 26973084

161. Gagne JJ, Han X, Hennessy S, Leonard CE, Chrischilles EA, Carnahan RM, Wang SV, Fuller C, Iyer A, Katcoff H, Woodworth TS, Archdeacon P, Meyer TE, Schneeweiss S, Toh S (2016). Successful comparison of US Food and Drug Administration Sentinel analysis tools to traditional approaches in quantifying a known drug-adverse event association. *Clinical pharmacology and therapeutics*, 100(5):558-564. PMID: 27416001
162. Vaughan Sarrazin MS, Jones M, Mazur A, Cram P, Ayyagari P, Chrischilles E (2017). Cost of hospital admissions in medicare patients with atrial fibrillation taking warfarin, dabigatran, or rivaroxaban *Journal of the American College of Cardiology* 69(3):360-362. PMID: 28104077
163. Palamaner Subash Shantha G, Bhave PD, Girotra S, Hodgson-Zingman D, Mazur A, Giudici M, Chrischilles E, Vaughan Sarrazin MS (2017). Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. *Circ Cardiovasc Qual Outcomes*, 10(4). PMID: 28408716
164. Kulchaitanaroaj P, Brooks JM, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL (2017). Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. *Journal of hypertension*, 35(1):178-187. PMID: 27684354
165. Mohr NM, Harland KK, Chrischilles EA, Bell A, Shane DM, Ward MM (2017). Emergency Department Telemedicine Is Used for More Severely Injured Rural Trauma Patients, but Does Not Decrease Transfer: A Cohort Study. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*, 24(2):177-185. PMID: 28187248
166. Carnahan RM, Brown GD, Letuchy EM, Rubenstein LM, Gryzlak BM, Smith M, Reist JC, Kelly MW, Schultz SK, Weckmann MT, Chrischilles EA (2017). Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes. *Alzheimer's & dementia (New York, N. Y.)*, 3(4):553-561. PMC: PMC5671632, PMID: 29124114
167. Ammann EM, Shanafelt TD, Larson MC, Wright KB, McDowell BD, Link BK, Chrischilles EA (2017). Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Clinical lymphoma, myeloma & leukemia*, 17(12):e11-e25. PMID: 28802891
168. Faine BA, Mohr N, Dietrich J, Meadow L, Harland KK, Chrischilles E (2017). Antimicrobial Therapy for Pneumonia in the Emergency Department: The Impact of Clinical Pharmacists on Appropriateness. *The western journal of emergency medicine*, 18(5):856-863. PMC: PMC5576621, PMID: 28874937
169. Chrischilles EA, Friedman S, Ritzwoller DP, Selby JV (2017). Patients, data, and progress in cancer care. *The Lancet. Oncology*, 18(11):e624-e625. PMID: 29208379
170. Zhou M, Wang SV, Leonard CE, Gagne JJ, Fuller C, Hampp C, Archdeacon P, Toh S, Iyer A, Woodworth TS, Cavagnaro E, Panozzo CA, Axtman S, Carnahan RM, Chrischilles EA, Hennessy S (2017). Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. *Epidemiology (Cambridge, Mass.)*, 28(6):838-846. PMID: 28682851
171. Ammann EM, Leira EC, Winiecki SK, Nagaraja N, Dandapat S, Carnahan RM, Schweizer ML, Torner JC, Fuller CC, Leonard CE, Garcia C, Pimentel M, Chrischilles EA (2017). Chart

validation of inpatient ICD-9-CM administrative diagnosis codes for ischemic stroke among IGIV users in the Sentinel Distributed Database. *Medicine*, 96(52):e9440. PMID: 29384925

172. Ammann EM, Cuker A, Carnahan RM, Perepu US, Winiecki SK, Schweizer ML, Leonard CE, Fuller CC, Garcia C, Haskins C, Chrischilles EA (2018). Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database. *Medicine*, 97(8):e9960. PMC: PMC5841980, PMID: 29465588
173. Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA (2018). Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. *Leukemia & lymphoma*, 59(3):643-649. PMID: 28718694
174. Chrischilles EA, Gagne JJ, Fireman B, Nelson J, Toh S, Shoaibi A, Reichman ME, Wang S, Nguyen M, Zhang R, Izem R, Goulding MR, Southworth MR, Graham DJ, Fuller C, Katcoff H, Woodworth T, Rogers C, Saliga R, Lin ND, McMahonill-Walraven CN, Nair VP, Haynes K, Carnahan RM (2018). Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. *Pharmacoepidemiology and drug safety*, 27(3):263-271. PMID: 29318683
175. Ammann EM, Schweizer ML, Robinson JG, Eschol JO, Kafa R, Girotra S, Winiecki SK, Fuller CC, Carnahan RM, Leonard CE, Haskins C, Garcia C, Chrischilles EA (2018). Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database. *Pharmacoepidemiology and drug safety*, 27(4):398-404. PMID: 29446185
176. Brooks JM, Chapman CG, Suneja M, Schroeder MC, Fravel MA, Schneider KM, Wilwert J, Li YJ, Chrischilles EA, Brenton DW, Brenton M, Robinson J (2018). Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right? *Journal of the American Heart Association*, 7(11). PMID: 29848495
177. Carter BL, Levy B, Gryzlak B, Xu Y, Chrischilles E, Dawson J, Vander Weg M, Christensen A, James P, Polgreen L (2018). Cluster-Randomized Trial to Evaluate a Centralized Clinical Pharmacy Service in Private Family Medicine Offices. *Circulation. Cardiovascular quality and outcomes*, 11(6):e004188. PMC: PMC5996776, PMID: 29884657
178. Carnahan RM, Kuntz JL, Wang SV, Fuller C, Gagne JJ, Leonard CE, Hennessy S, Meyer T, Archdeacon P, Chen CY, Panozzo CA, Toh S, Katcoff H, Woodworth T, Iyer A, Axtman S, Chrischilles EA (2018). Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and *Clostridium difficile* infection. *Pharmacoepidemiology and drug safety*, 27(7):731-739. PMID: 29532543
179. Goedken AM, Brooks JM, Milavetz G, Rudzianski NJ, Chrischilles EA (2018). Geographic variation in inhaled corticosteroid use for children with persistent asthma in Medicaid. *The Journal of asthma : official journal of the Association for the Care of Asthma*, 55(8):851-858. PMID: 28800267

180. Leone JP, Haraldsson B, Mott SL, McDowell BD, Chrischilles EA (2019). Treatment Patterns and Survival of Elderly Patients With Breast Cancer Brain Metastases. *American journal of clinical oncology*, 42(1):60-66. PMID: 29965807
181. Neuner JM, Kong A, Blaes A, Riley D, Chrischilles E, Smallwood A, Lizarraga I, Schroeder M (2019). The association of socioeconomic status with receipt of neoadjuvant chemotherapy. *Breast cancer research and treatment*, 173(1):179-188. PMID: 30232683
182. Carnahan RM, Gagne JJ, Hampp C, Leonard CE, Toh S, Fuller C, Hennessy S, Hou L, Cocoros NM, Panucci G, Woodworth T, Cosgrove A, Iyer A, Chrischilles EA (2019). Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. *Pharmaceutical Medicine*, 33(1):29-43.
183. Haskins CB, McDowell BD, Carnahan RM, Fiedorowicz JG, Wallace RB, Smith BJ, Chrischilles EA (2019). Impact of preexisting mental illness on breast cancer endocrine therapy adherence. *Breast cancer research and treatment*, 174(1):197-208. PMC: PMC6426454, PMID: 30465157
184. Mora-Pinzon MC, Chrischilles EA, Greenlee RT, Hoeth L, Hampton JM, Smith MA, McDowell BD, Wilke LG, Trentham-Dietz A (2019). Variation in coordination of care reported by breast cancer patients according to health literacy. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 27(3):857-865. PMC: PMC6355372, PMID: 30062586
185. Japuntich SJ, Kumar P, Pendergast JF, Juarez Caballero GY, Malin JL, Wallace RB, Chrischilles EA, Keating NL, Park ER (2019). Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*, 21(4):497-504. PMID: 29351659
186. Chrischilles EA, Riley D, Letuchy E, Koehler L, Neuner J, Jernigan C, Gryzlak B, Segal N, McDowell B, Smith B, Sugg SL, Armer JM, Lizarraga IM (2019). Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network. *Breast cancer research and treatment*, 175(3):675-689. PMID: 30852760
187. Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J (2019). An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. *JCO clinical cancer informatics*, 3:1-15. PMID: 31335166
188. Charlton ME, Shahnazi AF, Gribovskaja-Rupp I, Hunter L, Mengeling MA, Chrischilles EA, Lynch CF, Ward MM (2019). Determinants of Rectal Cancer Patients' Decisions on Where to Receive Surgery: a Qualitative Analysis. *Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract*, 23(7):1461-1473. PMC: PMC6409182, PMID: 30203231
189. Chioreso C, Gao X, Gribovskaja-Rupp I, Lin C, Ward MM, Schroeder MC, Lynch CF, Chrischilles EA, Charlton ME (2019). Hospital and Surgeon Selection for Medicare Beneficiaries With Stage II/III Rectal Cancer: The Role of Rurality, Distance to Care, and Colonoscopy Provider. *Annals of surgery*. PMID: 31714306

190. Blaes AH, Jewett PI, McKay K, Riley D, Jatoi I, Trentham-Dietz A, Chrischilles E, Klemp JR (2019). Factors associated with genetic testing in a cohort of breast cancer survivors. *The breast journal*, 25(6):1241-1244. PMID: 31270889
191. Mendy A, Metwali N, Perry SS, Chrischilles EA, Wang K, Thorne PS (2020). Household endotoxin reduction in the Louisa Environmental Intervention Project for rural childhood asthma. *Indoor air*, 30(1):88-97. PMID: 31605641
192. McDowell BD, Klemp J, Blaes A, Cohee AA, Trentham-Dietz A, Kamaraju S, Otte JL, Mott SL, Chrischilles EA (2020). The association between cancer care coordination and quality of life is stronger for breast cancer patients with lower health literacy: A Greater Plains Collaborative study. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 28(2):887-895. PMC: PMC6893112, PMID: 31168710
193. Briasoulis A, Gao Y, Inampudi C, Alvarez P, Asleh R, Chrischilles E, Leira EC, Vaughan-Sarrazin M (2020). Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses. *BMC cardiovascular disorders*, 20(1):42. PMC: PMC6998084, PMID: 32013886
194. Chang NN, Reisinger HS, Schweizer ML, Jones M, Chrischilles E, Chorazy M, Huskins C, Herwaldt L (2020). Hand Hygiene Compliance at Critical Points of Care. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. PMID: 32034404

2. Non-Peer-Reviewed Papers (reports, proceedings, etc.)

1. Chrischilles EA (1992). The contribution of epidemiology to pharmaco-economic research. *Drug Info J*, 26:219-229.
2. Chrischilles EA (1996). Outcomes assessment in osteoporosis: Strategies for improvement. *Medical Interface* 9(7):127-133.
3. Chrischilles EA, Sorofman BA, Ziegrowsky MB, Davis C (1997). The Iowa online prospective drug utilization review (OPDUR) demonstration project: Study design, system design, and conceptual models. *J Res Pharmaceutical Economics*, 8:171-191.
4. Rubenstein LM, Chrischilles EA, Voelker MD (1998). The impact of Parkinson's disease on health status, health expenditures and productivity: Estimates from the National Medical Expenditure survey. *Focus on Parkinson's Disease* 10(2):102-104.
5. Brooks JM, Chrischilles EA (2001). Research highlights the 'art' of medicine. *The Wall Street Journal*

3. Books/Monographs

4. Chapters

1. Chrischilles EA, Nduaguba M, Wallace RB, Semla TP (1989). Psychotropic drug use and use and health outcomes in nursing homes. S.A. Edlavitch (Ed.), *Pharmacoepidemiology*., Chelsea, MI:

2. Chrischilles EA (1991). Cost-effectiveness analysis. J.L. Bootman, R.J. Townsend, & W.F. McGhan (Eds.), *Principles of Pharmacoeconomics: Implications for drug therapy decisions.*, Cincinnati, OH: *Harvey Whitney Books*
3. Chrischilles EA (1994). What are the necessary and desirable attributes of the research infrastructure for studying patient outcomes of pharmaceutical care interventions? Patient Outcomes of Pharmaceutical Interventions: A Scientific Foundation for the Future. *American Pharmaceutical Association* 83-91.
4. Chrischilles EA, Sorofman B (1996). Pharmaceutical Care and Community Practice: The Status of Pharmaceutical Care Integrating Pharmaceutical Care into Community Practice *Pharmaceutical Care in the United States.* 29-40.
5. Chrischilles EA (1996). Cost-effectiveness analysis. J.L. Bootman, R.J. Townsend, & W.F. McGhan (Eds.), *Principles of Pharmacoeconomics: Implications for drug therapy decisions.*, Cincinnati, OH: *Harvey Whitney Books* (2nd ed.).

5. Electronic Publications

1. Witry MJ, Doucette WR, Daly JM, Levy BT, Chrischilles EA (2010). Family physician perceptions of personal health records. *Perspectives in Health Information Management*, <http://perspectives.ahima.org/>:
2. Archdeacon P, Buse J, Califf R, Choudhry N, Chrischilles E, Connor S, Curtis J, Ellenberg S, Evans B, Fortmann S, Hernandez A, Hornbuckle K, Lavezzari G, Levy E, Madre L, Mahon E, Mannello E, McGraw D, Mikita JS, Mushlin A, Nair V, Perlmutter J, Platt R, Psaty B, Raebel M, Rosati K, Rosenfeld S, Spettell C, Tenaerts P, McMahonill-Walraven C (2014). Developing approaches to conducting randomized trials using the Mini-Sentinel distributed database
3. Carnahan R, Gagne J, Nelson J, Fireman B, Shoabi A, Reichman M, Zhang R, Levenson M, Graham D, Tiwari R, Southworth MR, Archdeacon P, Charkravarty A, Goulding M, Brown J, Fuller C, Toh D, Chrischilles E (2014). Mini-Sentinel prospective routine observational monitoring program tools (PROMPT): rivaroxaban surveillance plan
4. Chrischilles EA, Winiecki SK, Fireman B, Carnahan RM, Schweizer ML, Leonard CE, Baker MA, Toh D, Cuker A (2014). Thromboembolic events after immunoglobulin administration. Mini-Sentinel Assessment Protocol

6. Abstracts

1. Chrischilles EA (1981). Cost-benefit analysis of the clinical pharmacist in family practice. *Seventh Annual Clinical Conference, University of Nebraska College of Pharmacy, Omaha, Nebraska*
2. Chrischilles EA (1982). Cost-benefit analysis of clinical pharmacy services in family practice residency programs. *American Society of Hospital Pharmacists Seventeenth Annual Midyear Clinical Meeting, Los Angeles, CA*
3. Chrischilles EA, Helling DK, Rowland CR (1982). Cost-benefit-analysis of the clinical pharmacist in family-practice. *Drug Intelligence & Clinical Pharmacy* 16(6):471-471.

4. Chrischilles EA (1983). Cost-effectiveness of a medication refill reminder system. *Drug Intelligence & Clinical Pharmacy* 17(6):441-441.
5. Chrischilles EA (1983). Evaluation of the effect of family practice clinical pharmacy services on appropriateness of physician prescribing. *American Society of Hospital Pharmacists Eighteenth Annual Midyear Clinical Meeting, Atlanta, GA*
6. Chrischilles EA (1984). Impact of pharmacist-physician patient care rounds on reducing drug costs in a long term care facility. *Fifth Annual Meeting of the American College of Clinical Pharmacy, San Diego, CA*
7. Chrischilles EA (1984). Impact of pharmacist-physician patient-care rounds on reducing drug costs in a long-term care facility. *Drug Intelligence & Clinical Pharmacy* 18(6):499-499.
8. Selma TP, Chrischilles EA, Helling DK, Lemke JH, Wallace RB (1986). The relationship of salicylate and nonsteroidal anti-inflammatory drug-use to tinnitus in an elderly population. *Drug Intelligence & Clinical Pharmacy* 20(6):472-472.
9. Chrischilles EA (1987). Psychotropic drug use and health outcome in nursing home patients. *Third International Pharmacoepidemiology Conference, Minneapolis, MN*
10. Chrischilles EA (1988). Prevalence and purpose of multiple analgesic drug use. *Fourth Annual International Pharmacoepidemiology Conference, Minneapolis, MN*
11. Chrischilles EA (1989). Medications with dental significance: Usage in a nursing home population. *IADR*
12. Chrischilles EA, Nduaguba M, Wallace RB, Semla TP (1989). Psychotropic-drug use and health outcomes in nursing homes. 3rd International Conference on Pharmacoepidemiology, Minneapolis, MN Sept 9-11, 1987 *Pharmacoepidemiology*, 1:325-331.
13. Chrischilles EA (1990). Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. *Sixth Annual International Pharmacoepidemiology Conference, Anaheim, CA*
14. Chrischilles EA (1994). A health policy model for evaluating interventions to achieve optimal calcium intake. *An International Conference on Adjuvant Nutrition and Chronic Disease: Preventive and Therapeutic Effects, Toronto, Ontario, Canada*
15. Chrischilles EA (1994). Public health interventions to promote calcium intake. *NIH Consensus Development Conference on Optimal Calcium Intake, Bethesda, MD*
16. Chrischilles EA (1995). The Iowa on-line prospective drug utilization review demonstration project. *APHA Drug Policy Study Group, San Diego, CA*
17. Chrischilles EA (1996). Pharmacists' cognitive services in an on-line drug use review (UPDUR) system in Iowa. *Empowering the Disadvantaged, American Public Health Association 124th Annual Meeting and Exposition, New York, NY*
18. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL (1997). The burdens of Parkinson's disease. *Twelfth International Symposium on Parkinson's Disease, London*

19. Chrischilles EA, Voelker MD, Rubenstein LM, Wallace RB, Rodnitzky RL (1997). The relationship of clinical variables to health related quality of life in Parkinson's disease. *Neurology* 48(3):Supplement 2, 4051-4051.
20. Chrischilles EA, Voelker MD, Rubenstein LM, Wallace RB, Rodnitzky RL (1997). The relationship of clinical variables to health-related quality of life in Parkinson's disease. *American Academy of Neurology 49th Annual Meeting, Boston, MA*
21. Scott SD, Carter WB, Hetherington NJ, Scholz DA, Chrischilles EA (1998). Chop utilization for intermediate and high grade NHL (IHL) in Iowa varies by treatment setting. *Blood* 92(10):Supplement 1, 240B-240B, Part 2, Meeting Abstract 4031.
22. Chrischilles EA, Rubenstein LM, Voelker MD (1998). The euro QOL in Parkinson's disease research: Rated current health vs. population-derived health state preferences. *International Society for Pharmaco-economics and Outcomes Research, Philadelphia*
23. Rubenstein LM, Voelker MD, Chrischilles EA (1998). Years of healthy life and the capacity to identify groups in need of health care and community service. *Am J Epi, Suppl* 147(11):Supplement S, S29-S29, Meeting Abstract 113.
24. Chrischilles EA, Voelker MD, Chen-Hardee SS, Klepser DG, Brooks JM, Scott SD, Link B, Delgado DJ (2002). A SEER-HCUP database study of neutropenia hospitalizations among newly diagnosed non-Hodgkin's lymphoma patients treated with chemotherapy. *Blood* 100(11):288B-288B, Part 2, Meeting Abstract 4686.
25. Chrischilles EA, Brooks JM, Scott SD, Chen-Hardee SS, Konety BR (2002). Age-specific effects of comorbidity, grade, and access on prostate cancer treatment choice. *Journal of Urology* 167(4):supplement S, 339-339.
26. Carnahan RM, Lund BC, Chrischilles EA, Perry PJ (2002). Antidepressant adherence in the Iowa Medicaid pharmaceutical case management population. *Pharmacotherapy* 22(10):1361-1361, Meeting Abstract 235.
27. Chrischilles EA, Merchant JA, Kuehl A, Ahrens R, Reynolds S, Burmeister LF, Kelly K, Thorne P (2002). Childhood asthma in a rural Iowa population. *American Public Health Association, Philadelphia*
28. Brooks JM, Klepser DG, Chrischilles EA, Voelker MD, Chen-Hardee SS, Scott SD, Link B, Delgado DJ (2002). Clinical factors associated with charges for neutropenia hospitalization among newly diagnosed non-Hodgkin's lymphoma patients treated with chemotherapy. *Blood* 100(11):501B-501B, Part 2, Meeting Abstract 5588.
29. Brooks JM, Chrischilles EA, Scott SD, Chen-Hardee SS, Konety BR (2002). Effectiveness of aggressive treatments for early stage prostate cancer: Evidence from SEER-Medicare using instrumental variable estimation. *Journal of Urology* 167(4):Supplement S, 70-70.
30. Kaboli PJ, Hoth AB, Carter B, Chrischilles EA, Shorr RI, Wagner PS, Rosenthal GE (2002). Lack of agreement between computerized medication profiles and structured medication histories. *J Gen Int Med* 17(Suppl 1):126-126.

31. Chrischilles EA, Wallace RB, Scholz D, Rubenstein L, VanGilder R, Wright K, Pavlik C (2002). Mobility limitations and secondary conditions among adult medicare beneficiaries. *American Public Health Association, Philadelphia*
32. Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA (2003). Cost-effectiveness of tamsulosin, doxazosin and terazosin in the treatment of benign prostatic hyperplasia. *Journal of Urology* 169(4):Supplement S, 345-345, Meeting Abstract DP27.
33. Brooks JM, Klepser D, Chrischilles EA, Voelker M, Chen-Hardee S, Scott S, Link B, Delgado D (2003). Effect of clinical factors on neutropenia-related inpatient charges among newly diagnosed non-Hodgkins lymphoma (NHL) during first course chemotherapy. *American Society of Clinical Oncology, Chicago*
34. Chrischilles EA, Rubenstein LM, Voelker MD, Wright KB, Link BK, Brooks JM, Delgado DJ (2003). Granulocyte colony-stimulating factor use during first course chemotherapy for non-Hodgkin's lymphoma: National SEER-medicare study. *Blood* 102(11):A499A-499A, Part 1, Meeting Abstract 1817.
35. Brooks JM, Zhao RB, Chrischilles EA, Pendergast JF, Flanigan MJ, Hunsicker LG (2003). Hemodialysis provider characteristics and early initiation of hemodialysis. *Journal of the American Society of Nephrology*, 14:Supplement S, 253A-253A.
36. Carter BL, Lund BC, Chrischilles EA, Hayase N (2003). Longitudinal analysis of antihypertensive drug interactions. *American Journal of Hypertension* 16(5):13A-13A, Part 2, Meeting Abstract OR31.
37. Brooks JM, Voelker MD, Chen-Hardee SS, Park TR, Wright KB, Link BK, Chrischilles EA, Rubenstein LM, Delgado DJ (2003). Neutropenia-related inpatient medicare costs during first course chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: National SEER-Medicare study. *Blood* 102(11):A498A-498A, Part 1, Meeting Abstract 18112.
38. Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Lyman GH (2003). Time to first febrile neutropenia among early stage breast cancer patients receiving adjuvant chemotherapy. *Pharmacotherapy* 23(3):406-406, Meeting Abstract 104.
39. Chrischilles EA, Voelker MD, Chen-Hardee S, Brooks JM, Scott S, Link B, Delgado D (2003). Time to first neutropenia hospitalization during chemotherapy for non-Hodgkin's lymphoma: an Iowa SEER-Medicare study. *American Society of Clinical Oncology, Chicago*
40. Voelker MD, Rubenstein LM, Chrischilles EA, Chen-Hardee SS, Link BK, Wright KB, Brooks JM, Delgado DJ (2003). Time to first neutropenia hospitalization during first course chemotherapy among newly diagnosed non-Hodgkin's lymphoma patients: National SEER-medicare study. *Blood* 102(11):253A-253A, Part 1, Meeting Abstract 888.
41. Flaum M, Lund BC, Chrischilles EA (2003). Trends in utilization of antipsychotics in three systems of care in Iowa: Prisons, Medicaid and Veterans Administration. *Schizophrenia Research* 60(1):Supplement S, 336-336.
42. Voelker MD, Chrischilles EA, Wright KB, Link BK, Park TR, Delgado DJ (2004). Factors associated with first course chemotherapy among older patients with newly diagnosed non-Hodgkin's lymphoma: National SEER-Medicare study. *Journal of Clinical Oncology, 2004*

ASCO Annual Meeting Proceedings 22(14):Supplement S, 548S-548S, Meeting Abstract 6118.

43. Swenson WT, Lynch CF, Wooldridge J, Forman-Hoffman VL, Chrischilles EA, Link BK (2004). Improved survival of follicular lymphoma patients in the surveillance, epidemiology, and end-results (SEER) program. *Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post Meeting Edition) 22(14S):6578.*
44. Kaboli P, Hoth A, Carter BL, Chrischilles EA, Shorr RI, Bhattacharyya A, Ness J, Rosenthal GE (2004). The VA enhanced pharmacy outpatient clinic (EPOC) study: A randomized controlled pharmacist-physician intervention trial. *Journal of General Internal Medicine, 19:Supplement 1, 227-227.*
45. Chrischilles EA, Thorne PS, Kuehl AK, Kelly KM, Schroeder A, O'Neill M, Walker R, Harris L, Quinones A (2005). An algorithm for identifying a population-based sample of children with frequent asthma symptoms. *Proceedings of the American Thoracic Society, San Diego*
46. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA (2005). Increased risk of extrapyramidal side effect treatment associated with atypical antipsychotic polytherapy. *Pharmacotherapy 25(3):474-474, Meeting Abstract 140.*
47. Thorne PS, Chrischilles EA, Kuehl AK, Kelly K, Netwali N, LEIP Field Group (2005). Indoor surface and airborne concentrations of endotoxin and $\beta(1-3,1-6)$ -glucans in the homes of rural asthmatic children. *Proceedings of the American Thoracic Society, San Diego*
48. Chrischilles EA, Klepser DG, Brooks JM, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ (2005). Effect of clinical characteristics on neutropenia-related inpatient costs among newly diagnosed non-Hodgkin's lymphoma cases during first-course chemotherapy. 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL May 31-June 3, 2003 *Pharmacotherapy 25(5):668-675.*
49. Brooks JM, Chrischilles EA, Chen-Hardee S, Cho E, Scott SD (2006). Estimating the effectiveness of early-stage lung cancer adjuvant treatments in practice using instrumental variable methods. *Value in Health 9(3):A104-A104.*
50. Zhao Y, Brooks JM, Chrischilles EA, Flanigan MJ, Pendergast JF, Hunsicker LG (2006). Factors influencing early nephrology care prior to hemodialysis initiation among elderly patients with end-stage renal disease. *Value in Health 9(3):A97-A97.*
51. Thorne PS, Chrischilles EA, Kuehl AW, Kelly KM, Metwali N, Harris LM, O'Neill ME, Quella AK, Walker RE (2006). Reduction of endotoxin and glucan exposures in the Louisa/Keokuk environmental intervention project (LEIP) for rural childhood asthma. *Journal of Allergy and Clinical Immunology 117(2):Supplement S, S215-S215.*
52. Brooks JM, Irwin CP, Hunsicker LG, Flanigan MJ, Chrischilles EA, Pendergast JF (2006). Effect of dialysis center profit-status on patient survival: A comparison of risk-adjustment and instrumental variable approaches. *Health Services Research 41(6):2267-2289.* 36th Annual Meeting of the American Society of Nephrology, San Diego, CA Nov. 12-17, 2003..
53. Link BK, Taylor MD, Brooks JM, Chrischilles EA, Lin M, Wright K, Pan L, Vose JM (2007). Correlates of treatment intensity for initial management of follicular lymphoma (FL) in

the United States: Report from the National Lymphocare Study (NLCS). *Blood* 110(11):769A-769A, Meeting Abstract 2612.

54. Zhao YM, Brooks JM, Flanigan MJ, Chrischilles EA, Pendergast JF, Hunsicker LG (2007). Short-term survival effect of early nephrology care prior to dialysis initiation in elderly patients with end-stage renal disease. *American Journal of Kidney Diseases* 49(4):A86-A86, Meeting Abstract 246.
55. Brooks JM, Chrischilles EA (2007). Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods. *Medical Care* 45(10):S123-S130. Symposium on Emerging Methods in Comparative Effectiveness and Safety, Rockville, MD, June 2006.
56. Kahn KL, Adams JL, Chrischilles EA, Harrington DP, Weeks JC, Ayanian JZ, Kiefe CI, Provenzale DT, Fletcher RH (2008). Are we use of chemotherapy for elderly stage III colon cancer patients? An analysis from the Cancer Care Outcomes & Research Surveillance Consortium (CanCORS). *Journal of Clinical Oncology* 26(15S):May 20 Supplement.
57. Carter B, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, Chrischilles EA, Franciscus CL, Xu YH (2010). A randomized-controlled effectiveness trial of physician/pharmacist collaboration to improve blood pressure control. *Pharmacy World & Science* 32(2):247-248.
58. Wan S, Brooks J, Chrischilles EA, Thomas A, Polgreen LA (2010). Effect of access to cancer care on age-specific utilization of chemotherapy among elderly women with metastatic breast cancer. *Value in Health* 13(3):A48-A48.
59. Carnahan RM, Lund BC, Chrischilles EA, Kaboli PJ (2010). Relation of symptom experience with anticholinergic drug exposure in older veterans. *Journal of Pharmacy Practice* 23(2):159.
60. Carter BL, Doucette WR, Franciscus CL, Ardery G, Kluesner KM, Chrischilles EA (2010). Deterioration of Blood Pressure Control After Discontinuation of a Physician-Pharmacist Collaborative Intervention *Pharmacotherapy* 30(3):228-235. 36th Annual Meeting of the North American Primary Care Research Group, San Juan PR, Nov. 15-19, 2008.
61. Hourcade JP, Chrischilles EA, Gryzlak BM, Hanson BM, Dunbar DE, Eichmann DA, Lorentzen RR (2011). Design Lessons for Older Adult Personal Health Records Software from Older Adults *Universal Access in Human-Computer Interaction: Users Diversity, PT 2* 6766(Part 2):176-185. 6th International Conference on Universal Access in Human Computer Interaction (UAHCI) 14th International Conference on Human Computer Interaction (HCI), Orlando, FL July 9-14, 2011.
62. Chen AB, Chen K, Weeks J, Chrischilles E, Malin J, Schrag D (2011). Palliative radiation therapy (RT) practice in metastatic non-small cell lung cancer (NSCLC) patients *International Journal of Radiation Oncology Biology Physics*, 81 (2):S590-S590.
63. Fang G, Chrischilles EA, Brooks JM, Carter BL, Robinson JG (2011). Substantial geographic variation in the use of tissue vs. non-tissue ACE inhibitors among elderly patients after acute myocardial infarction in the US. *Pharmacoepidemiology and Drug Safety*, 20:Supplement 1, S93-94, Meeting Abstract 215.

64. Charlton ME, Jiang D, Lin C, Stitzenberg KB, Pendergast JF, Chrischilles EA, Wallace RB (2011). Factors associated with use of preoperative chemoradiotherapy for rectal cancer *Journal of Clinical Oncology* 29(15):Supplement S, Meeting Abstract e14079.
65. Tien YY, Brooks J, Wright K, Link B, Chrischilles EA (2012). Diffusion of non-guideline experience-based chemotherapy care. *Value in Health* 15(7):A626-A626.
66. Abu Hejleh T, Chrischilles EA, Halfdanarson TR, Pendergast JF, Jiang DF, Smith CJ, Porter AT, Wallace RB (2012). Do patients with advanced-stage non-small cell lung cancer (AS NSCLC) live longer if managed within a clinical trial setting? *Journal of Clinical Oncology* 30(15):Supplement S: Meeting Abstract: 6034.
67. AlEjjeilat R, Chrischilles EA, Denburg NL, Link BK, Smith B, West MM, Eddy S, Rudzianski NJ, Murry J (2012). Genetic variation and chemotherapy response in lymphoma patients. *Clinical Pharmacology & Therapeutics*, 91:Supplement 1, S111-S111.
68. Chen AB, Cronin A, Weeks J, Chrischilles E, Malin J, Hayman J, Schrag D (2012). Patient beliefs about palliative radiation therapy (RT) in incurable lung cancer *International Journal of Radiation Oncology Biology Physics*, 84 (3):S1-S1.
69. Lund BC, Hillis SL, Chrischilles EA (2013). Adverse outcomes of polysedative use in veterans with PTSD. *Journal of General Internal Medicine*, 28:S18-S19, Supplement 1.
70. McDowell BD, Smith BJ, Button AM, Howe JR, Chrischilles EA, Mezhir JJ (2013). An assessment of the impact of geographic variation on resection rates and survival for early-stage pancreatic adenocarcinoma. *Journal of Clinical Oncology* 31(15):Supplement S, Meeting Abstract e15052.
71. Moga DC, Carnahan RM, Lund BC, Pendergast J, Wallace R, Torner J, Li Y, Chrischilles EA (2013). Bladder antimuscarinics use in veterans affairs community living Centers. *Pharmacoepidemiology and Drug Safety*, 22:482-483, Supplement 1, Special Issue S1, Meeting Abstract 965.
72. Chrischilles EA, Abu Hejleh T, Carter KD, Pendergast JF, Halfdanarson TR, Fletcher RH, Wallace RB (2013). Comorbidity and survival for patients with advanced-stage non-small cell lung cancer. *Journal of Clinical Oncology* 31(15):Supplement S, Meeting Abstract e19065.
73. McDowell BD, Howe JR, Chrischilles EA, Mezhir JJ (2013). Effect of geographic variability for pancreatectomy rates on outcomes in patients with stage I and II pancreatic adenocarcinoma. *Journal of Clinical Oncology* 31(4):Supplement S, Meeting Abstract 240.
74. McDowell B, Howe JR, Chrischilles EA, Mezhir JJ (2013). Geographic variability for pancreatectomy in patients with Stage I and II pancreatic adenocarcinoma: Low resection rates predict worse outcomes. *Annals of Surgical Oncology*, 20:Supplement 1, S118-S118.
75. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D (2013). Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. 53rd Annual Meeting of the American-Society-of-Radiation-Oncology (ASTRO) *Journal of Clinical Oncology* 31(5):558-564.

76. Abu Hejleh T, Chrischilles EA, Pendergast JF, Porter AT, Wallace RB (2013). Survival of non-small cell lung cancer (NSCLC) patients with and without diabetes mellitus (DM): Findings from the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). *Journal of Clinical Oncology* 31(15):Supplement S, Meeting Abstract 6602.
77. Charlton ME, Stitzenberg KB, Lin C, Juarez GH, Halfdanarson TR, Pendergast JF, Chrischilles EA, Wallace RB (2014). Long-term quality of life (QoL) for stage II/III rectal cancer survivors in the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). *Journal of Clinical Oncology* 32(3):Supplement S, Meeting Abstract 584.
78. Thomas A, Khan SA, Schroeder MC, Chrischilles EA, Lizarrage I, Sugg SL (2014). Local therapy and overall survival for Stage IV breast cancer: SEER 1988-2010 *Journal of Clinical Oncology* 32(15):Supplement S, Meeting Abstract 1090. 50th Annual Meeting of the American Society of Clinical Oncology May 30-June 3, 2014.
79. Abu Hejleh T, Chrischilles EA, Pendergast JF, Juarez GY, Wallace RB (2014). The effect of body mass index (BMI) on non-small cell lung cancer (NSCLC) mortality *Journal of Clinical Oncology* 32(15):Supplement S, Meeting Abstract e19041. 50th Annual Meeting of the American Society of Clinical Oncology May 30-June 3, 2014.
80. Wright AA, Keating NL, Ayanian J, Chrischilles EA, Kahn KL, Ritchie C, Earle C, Landrum MB (2015). Family perspectives on aggressive cancer care near the end of life. *Journal of Clinical Oncology* 33(15):Supplement S, Meeting Abstract 6517. Annual Meeting of the American-Society-of-Clinical-Oncology (ASC), Chicago IL, May 29-June 2.
81. Reichman ME, Bartels D, Carnahan RM, Chrischilles EA, Gagne JJ, Go AS, Toh D (2015). Safety Surveillance of New Anticoagulants within the Mini-Sentinel Program-Progress, Challenges, and Future Directions *Pharmacoepidemiology and Drug Safety*, 24:417-417, Supplement 1, Special Issue SI, Meeting Abstract 731.
82. Gagne JJ, Han X, Hennessy S, Leonard CE, Chrischilles EA, Carnahan RM, Wang SV, Fuller C, Iyer A, Katchoff H, Woodworth TS, Archdeacon P, Meyer TE, Schneeweiss S, Toh S (2016). Assessment of the US Food and Drug Administration's sentinel analysis tools: Angiotensin-converting enzyme inhibitors and angioedema *Pharmacoepidemiology and Drug Safety*, 25:503-503, Supplement S3, Meeting Abstract 866.
83. Ammann EM, Haskins CB, Fillman KM, Ritter RL, Gu X, Winiecki SK, Carnahan RM, Torner JC, Fireman BH, Jones MP, Chrischilles EA (2016). Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of randomized controlled trials *Pharmacoepidemiology and Drug Safety* 25(440-440, Supplement S3, Meeting Abstract 756).
84. Zhou M, Wang SV, Leonard CE, Gagne JJ, Fuller C, Hampp C, Archdeacon P, Toh S, Iyer A, Woodworth TS, Cavagnaro E, Panozzo C, Axtman S, Carnahan RM, Chrischilles EA (2016). Pilot test of the sentinel modular program for propensity-score matched cohort analyses: Application to glyburide, glipizide, and severe hypoglycemia *Pharmacoepidemiology and Drug Safety*, 25:56-57, Supplement S3, Meeting Abstract 89.
85. Garcia CJ, Fuller CC, Chrischilles EA, Pimentel M, Carnahan RM, Fireman BH, Schweizer ML, Leonard CE, Cuker A, Leira EC, Robinson JG, Winiecki SK, Baker MA, Ammann EM (2017). Practical lessons learned for identification of thromboembolic events and intravenous

immunoglobulin exposure in the Sentinel distributed database *Pharmacoepidemiology and Drug Safety*, 26:236-237, Supplement 2, Meeting Abstract 391.

86. Chrischilles EA, Gagne J, Fireman B, Nelson JC, Toh S, Shoaibi A, Reichman ME, Wang SV, Nguyen MD, Zhang RM, Izem I, Goulding MR, Southworth MR, Graham DJ, Fuller CC, Katcoff H, Woodwoth TS, Rogers C, Saliga RM, Lin ND, McMahonill-Walraven CN, Nair VP, Haynes K, Carnahan RM (2017). Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration sentinel system *Pharmacoepidemiology and Drug Safety*, 26:450-450, Supplement 2, Meeting Abstract 746.
87. Ammann EM, Chrischilles EA, Carnahan RM, Fireman BH, Fuller CC, Schweizer ML, Garcia C, Pimentel M, Leonard CE, Baker MA, Cuker AC, Leira EC, Robinson JG, Winiacki SK (2017). Self-controlled assessment of thromboembolic events (TEEs) risk following intravenous immune globulin (IGIV) *Pharmacoepidemiology and Drug Safety*, 26:226-226, Supplement 2, Meeting Abstract 374.
88. McDowell BD, Klemp J, Blaes A, Cohee AA, Trentham-Dietz A, Kamaraju S, Otte JL, Rock JL, Rubenstein L, Chrischilles EA (2017). Survivorship care planning is associated with breast cancer survivors' reported quality and coordination of care *Cancer Research*, 77:Supplement 4, Meeting Abstract PD4-05. San Antonio Breast Cancer Symposium, San Antonio, TX Dec. 6-10, 2016.
89. Chrischilles EA, Gryzlak B, McDowell BD, Connolly DW, Waitman R (2017). The share thoughts on breast cancer study: A Greater Plains collaborative cohort characterization project *Cancer Research*, 77:Supplement 4, Meeting Abstract P5-08-23. San Antonio Breast Cancer Symposium, San Antonio, TX Dec. 6-10, 2016.
90. Haraldsson B, Leone JP, McDowell BD, Chrischilles EA, (2017). Treatment patterns for breast cancer brain metastasis *Cancer Research*, 77:Supplement 4, Meeting Abstract P5-08-26. San Antonio Breast Cancer Symposium, San Antonio, TX Dec. 6-10, 2016.
91. Charlton ME, Chioreso C, Gribovskaja-Rupp I, Lin C, Ward MM, Lynch CF, Chrischilles EA, (2018). Predictors of rectal cancer resection at high-volume hospitals among Medicare patients *Journal of Clinical Oncology* 36(4):Supplement S, Meeting Abstract 808, Gastrointestinal Cancers Symposium, San Francisco, CA, Jan. 18-20, 2018.
92. Charlton ME, Shahnazi A, Gribovskaja-Rupp I, Lin C, Hunter L, Chrischilles EA, Lynch CF, Ward MM (2018). Qualitative analysis of Iowa rectal cancer patients' decisions on where to receive surgery *Journal of Clinical Oncology* 36(4):Supplement S, Meeting Abstract 835, Gastrointestinal Cancers Symposium, San Francisco, CA, Jan. 18-20, 2018.
93. Huang C, Schroeder M, Chrischilles EA (2019). The contribution of function-related indicators (FRI) in identifying and modeling patient complexity *Value in Health*, 22:S105-S106, Supplement 2, Meeting Abstract PCN260.

7. Other

1. Chrischilles EA (1996). The Merck Manual of Geriatrics, 2nd Edition. Abrams WB, Beers MH and Berkow R (eds). Published by Merck & Co., Inc. Watehouse Station, NJ. *Annals of Pharmacotherapy* 30(1503).

2. Chrischilles EA, Kuehl AK, Sorofman BA, et al (1997). Continuous pharmaceutical care: a community-based demonstration project, Final Report. *Submitted to the research foundations of the American Pharmaceutical Association, the American Society of Consultant Pharmacists, and the American Society of Health System Pharmacists*
3. Chrischilles EA, Mahrenholz J (1997). Iowa Medicaid OPDUR Demonstration Project Annual Report, HCFA Cooperative Agreement No. 11-C-90232/7.
4. Chrischilles EA, Mahrenholz J (1998). Iowa Medicaid OPDUR Demonstration Project Continuation Year Final Report, HCFA Cooperative Agreement No. 11-C-90232/7.
5. Ammann EM, Chrischilles EA (2017). A reply to Ovanesov et al. *American journal of hematology* PMID: 28066921

B. Areas of Research Interest/Current Projects

1. Applied Surveillance Core – Protocol Core Co-Director (Current Project)
2. Cancer Center Support Grant – Supervise the Population Research Core (Current Project)
3. Cancer outcomes in practice (Area of Research Interest)
4. Collaborative physician-pharmacist management of hypertension (Current Project)
5. Comparative effectiveness research (Area of Research Interest)
6. Comparative effectiveness research of pharmacotherapy strategies for complex patients with acute myocardial infarction. (Current Project)
7. Developing a function-related index from claims data for complex patient comparative effectiveness research in cardiovascular disease (Current Project)
8. Medication use and effects among the elderly (Area of Research Interest)
9. Patient-centered outcomes research (Area of Research Interest)
10. Personal health records and elder medication use quality (Current Project)
11. Pharmacoepidemiology (Area of Research Interest)
12. Share Thoughts on Breast Cancer Study - a multicenter survey of breast cancer patients iwth medical record linkage (Current Project)
13. UI Clinical and Translational Science Program – Comparative Effectiveness Research Thematic Area Director (Current Project)
14. Web-enabled pharmacist-managed cardiovascular risk service with mHealth features (Current Project)

C. Sponsored Research (*ALL grants*)

(if you are not the PI, state your role or contributions - in a few sentences)

1. Grants Received

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
American Society of Hospital Pharmacists Research Foundation <i>Cost-benefit analysis of clinical pharmacy services in family practice residency programs</i> Elizabeth A. Chrischilles, <i>Co-Principal Investigator</i>		\$2,500 01/01/1982-12/31/1982
Family Health Foundation of America <i>Evaluation of the effect of family practice clinical pharmacy services on the quality of physician prescribing</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>		\$5,000 01/01/1983-12/31/1985
Iowa City Veterans Administration Medical Center (PhD dissertation research) <i>Assessment of extent and appropriateness of drug use in VA outpatients</i> Elizabeth A. Chrischilles, <i>Supporting</i>		\$10,000 01/01/1984-12/31/1986
Iowa City Veterans Administration Medical Center <i>Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline</i> Elizabeth A. Chrischilles, <i>Investigator</i>		\$10,000 01/01/1985-12/31/1986
Burroughs Wellcome Fund <i>Burroughs Wellcome Scholar Award in Pharmacoepidemiology</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	75%	\$250,000 01/01/1987-12/31/1992
Family Health Foundation of America <i>Treatment of pressure sores: cost-effectiveness of alternative treatment strategies</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$23,548 01/01/1988-12/31/1990
Norwich-Eaton Pharmaceuticals <i>Cost-effectiveness of osteoporosis therapy</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	25%	\$65,691 01/01/1989-12/31/1991

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
N01-AG-02106 NIA <i>Established Populations for Epidemiologic Study for the Elderly, Geriatric Pharmacology Project and Drug Code Revision</i> Elizabeth A. Chrischilles, <i>Investigator</i>	30%	\$30,000 01/01/1990-12/31/1991
Iowa Pharmacy Foundation <i>Statewide Drug Use Surveillance Survey</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	5%	\$6,000 01/01/1990-12/31/1991
P30 ES005605 <i>Environmental Health Sciences Research Center</i> Peter Thorne, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i>	5%	\$2,461,076 09/29/1990-03/31/2017
Robert Woods Johnson <i>Iowa hospital quality assessment and enhancement institute</i> Elizabeth A. Chrischilles, <i>Investigator</i>	15%	\$244,178 01/01/1991-12/31/1996
Iowa Pharmacy Foundation <i>Pharmaceutical care provided in a community pharmacy</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$40,000 01/01/1992-12/31/1999
11-C-90232/7 HCFA <i>Iowa On-line Prospective Drug Utilization Review Demonstration Project</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	30%	\$1,396,340 01/01/1992-12/31/1998
P20-AG09682 NIA <i>Center for Research on Older Rural Populations</i> Elizabeth A. Chrischilles, <i>Investigator</i>	15%	\$26,349 01/01/1992-12/31/1993

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
SmithKline Beecham-Consumer Brands <i>Cost-effectiveness of calcium carbonate therapy for osteoporosis</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$39,976 01/01/1992-12/31/1993
Pfizer Pharmaceuticals <i>Inpatient direct costs and long-term functional health impact of E5 monoclonal antibody for suspected gram negative sepsis</i> Elizabeth A. Chrischilles, <i>Investigator</i>	13%	\$133,474 01/01/1992-12/31/1993
The Upjohn Company <i>Cost and functional health effects of Parkinson's disease</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	15%	\$269,171 01/01/1993-12/31/1997
Marion Merrell Dow <i>Health economics postdoctoral fellowship</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$100,000 01/01/1993-12/31/1995
Robert Woods Johnson/Pew <i>A community-university partnership in rural health care and prevention</i> Elizabeth A. Chrischilles, <i>Investigator</i>	5%	\$125,000 01/01/1993-12/31/1995
588GW00 Iowa Department of Public Health <i>Persian Gulf Research Project</i> Elizabeth A. Chrischilles, <i>Investigator</i>	5%	\$1,281,601 01/01/1994-12/31/1996
American Pharmaceutical Association <i>Short-Run Advancement of APHA Science Initiative</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	0%	01/01/1994-06/30/1994
Procter & Gamble Company <i>Osteoporosis Forecasting Model</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	0%	\$20,450 07/29/1994-12/31/1999

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
ASCP/ASHP/APHA <i>Continuous pharmaceutical care</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$30,000 01/01/1995-12/31/1997
Marion Merrell Dow, Inc. <i>Economic analysis of DZPR0183</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$55,083 01/01/1995-12/31/1996
University of Illinois <i>Cost-Effectiveness of Pharmacy Study</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	0%	\$6,000 04/01/1995-06/30/1995
AMGEN <i>Assessing the clinical management of chemotherapy-related neutropenia for patients undergoing treatment for aggressive non-Hodgkins lymphoma or non-metastatic breast cancer</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	15%	\$241,616 01/01/1996-12/31/1998
Merck & Co., Inc. <i>Fracture Intervention Trial Health Economic Substudy Analysis Vertebral Arm</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	20%	\$31,646 01/01/1996-12/31/1998
CCP/Merck and Company <i>Pharmacoeconomics fellowship</i> Elizabeth A. Chrischilles, <i>Supporting</i>	10%	\$22,500 01/01/1996-12/31/1997
American College of Clinical Pharmacy <i>Richard Stanford/Clinical Pharmacy Research Fellowship</i> Elizabeth Chrischilles, <i>Principal Investigator</i>		\$22,500 07/01/1996-06/30/1997
5889DP02 CDC/Iowa Department of Public Health <i>Disability Data Analysis Contract</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$264,354 01/01/1997-12/31/2001

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Pharmacia & Upjohn Company <i>Costs and Health Effects of Parkinson's Disease Extension. Data Preparation and Delivery to Research Triangle Institute</i> Elizabeth Chrischilles, <i>Principal Investigator</i>		\$264,354 01/01/1997-12/31/2001
NIEHS/EPA/CDC Asthma SCOR <i>The etiology and pathogenesis of airways disease in children</i> David Schwartz, <i>Principal Investigator</i> Elizabeth A. Chrischilles	15%	\$414,137 01/01/1998-12/31/2003
DAMD17-98-1-8486 DOD <i>Unbiased Estimates from Retrospective Data for Prostate Cancer</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	20%	\$252,097 01/01/1998-12/31/2002
NCI <i>SEER Special Study Linked Databases For Breast Cancer</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$49,831 01/01/1998-12/31/1999
P01 ES09607 NIH <i>Asthma Center - Airway Disease in Children from Rural Communities</i> Gary Hunninghake, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	10%	\$1,661,528 11/01/1998-10/31/2004
Boehringer Ingelheim <i>Respiratory medication compliance in a large managed care organization</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	20%	\$305,131 02/01/1999-08/31/2000
IIR-98152-1 VA: HSR & D Gary Rosenthal, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Investigator</i>	20%	\$200,000 07/01/1999-06/30/2002

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Boehringer-Ingelheim Pharmaceuticals, Inc. <i>Alpha blocker medication patterns in a large Medigap insurance database</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$77,999 09/01/1999-08/31/2000
Wellmark Foundation/Iowa Medical Society <i>Statewide model of antibiotic resistance</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$70,500 03/30/2000-09/30/2002
MED-00-139 Iowa Dept. of Human Services <i>Pharmaceutical Case Management</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	21.5%	\$586,499 04/01/2000-03/31/2003
N01-DK-0-2401, Modification 1 NIH <i>United States Renal Data System Special Studies Centers (USRDS-SSCs)</i> Lawrence Hunsicker, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	8%	\$365,276 04/10/2000-03/31/2007
5881DP04 IDPH/NIH <i>Prevention of Secondary Conditions Interventions</i> Don VanDyke, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	0%	\$55,947 07/01/2000-06/30/2016
CDC <i>Care access, drug effects, aging and mobility disability</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	25%	\$684,354 09/30/2000-09/29/2004
5881AH01 IDPH/NIH <i>Asthma Surveillance in Iowa</i> Laurence Fuortes, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	0%	\$37,037 11/01/2000-09/30/2001

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Association of Occupational and Environmental Clinics <i>Midwestern Regional Pediatric Environmental Health Center</i> Joel Kline, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	0%	\$235,514 02/01/2001-09/30/2004
U.S. Dept. of Veterans Affairs <i>Randomized, Controlled Trial of Enhanced Pharmacy Care in Older Veteran Outpatients</i> Elizabeth Chrischilles	8.5%	\$31,800 04/01/2001-09/30/2003
5U01CA93339 NIH <i>CanCORS-Lung Cancer Outcomes/Surveillance Consortium-Iowa</i> Robert B. Wallace, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Principal Investigator</i>	15%	\$2,489,573 09/01/2001-08/31/2009
R01 ES11392 NIH <i>Exposure Intervention in a Rural Pediatric Asthma Cohort</i> Peter Thorne, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i>	10%	\$1,334,151 09/30/2001-07/31/2007
AMGEN, Inc. <i>Impact of Patient and Provider Characteristics on the Treatment, Outcomes and Costs of Neutropenia Among Patients with NHL</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$314,603 11/12/2001-01/22/2004
IDPH <i>State Capacity Building Project</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	3%	\$209,837 04/01/2002-03/31/2005

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
5R01 CA095961-02 NIH <i>A GIS Based Workbench to Interpret Cancer Maps</i> Gerald Rushton, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$905,505 05/01/2002-04/30/2005
Boehringer Ingelheim Pharmaceuticals, Inc <i>Development of a Cost-Effectiveness Model for Tamsulosin in the Treatment of Benign Prostatic Hyperplasia (BPH)</i> Robert Ohsfeldt, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	0%	\$58,279 05/17/2002-05/17/2003
R01 HL069801 NIH: National Heart, Lung and Blood <i>Collaborative Management of Hypertension</i> Barry Carter, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$1,379,753 07/01/2003-06/30/2007
R01 HL070740 NIH: National Heart, Lung and Blood <i>Improving Adherence to Blood Pressure Guidelines</i> Barry Carter, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$2,389,022 08/01/2003-07/30/2010
1P20CA10367201 NIH <i>Integrating Aging and Cancer Research</i> Robert B. Wallace, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	22%	\$1,259,366 09/29/2003-08/31/2010
UI/MC Lymphoma SPORE/National Cancer Institute <i>Heterogeneity of Treatment Benefit by Grade of Follicular Lymphoma</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	2%	\$45,731 01/01/2004-12/31/2004

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
1R01AG022913-01 NIH <i>Health and Health Services Use in the HRS/AHEAD</i> Fredric Wolinsky, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	15%	\$1,213,254 09/15/2004-06/30/2010
150014.0003 Am 1 Harvard Medical School <i>Local Therapy of Breast Cancer in Community Populations</i> John Brooks, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i>	10%	\$116,541 04/05/2005-02/28/2009
5P30CA086862 NIH <i>Cancer Center Support Grant (CCSG)</i> George Weiner, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Associate Director</i>	10%	\$31,991,024 07/01/2005-03/31/2021
<i>Total Project Costs: \$46,977,331 for period 7/14/2000-03/31/21</i>		
W81XWH US DOD <i>Prostate Cancer Research Training Program</i> David Lubaroff, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Supporting</i>	0%	\$737,191 01/15/2006-03/31/2015
5 U18 HS016094 AHRQ <i>University of Iowa Older Adults CERT</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	25%	\$2,787,229 04/14/2006-03/31/2012
5 R01 DD000107 CDC <i>Pharmaceutical Case Management and Living Well with a Disability</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	10%	\$664,035 09/30/2006-09/29/2010

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Community Pharmacy Foundation <i>An Initial Evaluation of Medication Therapy Management (MTM) Services in the Upper Midwest</i> William Doucette, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	2.5%	\$93,700 01/23/2007-06/30/2008
HHSA 290 2007 10012 & Mod 1 AHRQ <i>Iowa Research Network (IRENE): A Rural Primary Care Practice Based Research Network</i> Barcey Levy, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	0%	\$329,484 01/31/2007-01/28/2012
Merck Company Foundation <i>Merck Predoctoral Fellowship in Epidemiology</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>		\$120,000 08/20/2007-06/30/2009
5 TL 1RR024981 DHHS/NIH <i>University of Iowa Clinical and Translational Science Program</i> Gary Hunninghake, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Project PI</i> Gary Rosenthal, <i>Principal Investigator</i>	5%	\$973,253 09/01/2007-07/31/2017
<i>Total Project Costs: \$41,778,766</i>		
5 R18 HS017034 AHRQ <i>Personal Health Records and Elder Medication Use Quality</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	20%	\$808,139 09/07/2007-08/31/2011
3 UL1 RR024979-04S1 DHHS/NIH <i>University of Iowa Clinical and Translational Science Program: Administrative Supplement-Comparative Effectiveness Research Workforce Development</i> Gary Rosenthal, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Investigator</i>	15%	\$8,571,054 09/17/2007-05/31/2012

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Pharmacy Quality Alliance <i>Demonstration of a Regional Coalition Model for Pharmacy Performance Reporting Through the Pharmacy Quality Alliance</i> William Doucette, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	2%	\$115,000 07/01/2008-11/16/2009
1 R01 HL091841-01A1 NIH <i>A collaborative model to improve BP control and minimize racial disparities-CCC</i> Barry Carter, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$3,575,077 04/15/2009-02/28/2015
Subcontract with Dana Farber Cancer Inst. (NIH) <i>CanCORS – Lung Cancer Outcomes/Surveillance Consortium – Iowa</i> Robert B. Wallace, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	11.5%	09/01/2009-07/31/2014
HHSF2232009100061 Subcontract with Harvard Pilgrim Health Care, Inc. FDA <i>Detection and Analysis of Adverse Events Related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i> Ryan Carnahan, <i>Principal Investigator</i>	15%	\$349,865 09/23/2009-09/11/2019
<i>Total Project Costs: \$1,812,190</i>		
1 R18 HS018353-01 AHRQ <i>Demonstration of Quality Improvement of Medication Therapy Management Services</i> William Doucette, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$1,307,467 09/30/2009-07/31/2014

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
1 R01 HS01838-01A1 AHRQ <i>Comparative Effectiveness of Treatment Combinations Post MI in the Elderly</i> John Brooks, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	10%	\$1,063,719 08/01/2010-05/31/2015
1 R24 HS019440-01 AHRQ <i>Enhanced Data to Accelerate Complex Patient Comparative Effectiveness Research</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	15%	\$686,056 08/01/2010-01/31/2013
HHSA290201000012I, Master Task Order Contract AHRQ <i>Developing Evidence to Inform Decisions about Effectiveness Research Network-2 (DEcIDE-2)</i> Chrischilles, <i>Investigator</i>	1%	\$18,068 08/18/2010-05/17/2013
1 RC4 CA153493-01 NIH <i>Enhancing Community-Based Cancer Control in Iowa</i> Barcey Levy, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	2%	\$812,620 08/30/2010-09/30/2013
5881HIT04 IDPH <i>University of Iowa Consumer Survey</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	0%	\$667 09/15/2010-12/31/2010
1 R18 HS019355-01 AHRQ <i>IA-ADAPT: Improving Antipsychotic Appropriateness in Dementia Patients</i> Ryan M. Carnahan, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$970,210 09/30/2010-09/29/2013

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
1 RC4 AG038635-01 NIH <i>Interpreting IV Estimates When Treatment Effects are Heterogeneous: ACE/ARBs and Race</i> John Brooks, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$1,177,991 09/30/2010-08/31/2013
1 R21 HS019574-01 AHRQ <i>Should High-Risk Statin Utilization Rates be Increased for Complex AMI Patients?</i> John Brooks, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	5%	\$281,136 09/30/2010-09/29/2012
American Society of Clinical Oncology <i>ASCO Study of Geographical Access to Oncology Care</i> Marcia M. Ward, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Investigator</i>	2%	\$204,093 11/01/2010-01/31/2013
University of Florida/NIH <i>Adaptive Comparative Effectiveness Trials for Comparing Two Treatments</i> Christopher S. Coffey, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Investigator</i>	6%	\$85,093 05/23/2011-03/31/2012
FDA HHSF2232009100061 Harvard Pilgrim Health Care, Inc./FDA <i>Detection and Analysis of Adverse Events Related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative. Preparing for Monitoring Blood and Blood Product Safety and Utilization during Influenza Pandemics in the US Phase 1</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	2.6%	\$5,329 09/23/2011-09/22/2012

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
1 UH2 AT007784-01 NIH <i>Nighttime Dosing of Anti-Hypertensive Medications: A Pragmatic Clinical Trial</i> Gary Rosenthal, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	20%	\$543,997 09/30/2012-12/31/2013
National Association of Chain Drug Stores Foundation <i>Integrating Community Pharmacists into a Medication Therapy Management Program Within an Accountable Care Organization</i> William Doucette, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	5%	\$262,850 12/18/2012-06/30/2015
HHSF22301006T-0003 Harvard Pilgrim Health Care, Inc./FDA <i>Protocol-based Assessment of Thromboembolic Events after Immunoglobulin Administration (IVIG)</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	3 months 25%	\$227,812 02/22/2013-08/31/2016
Patient-Centered Outcomes Research Institute <i>Extension Connection: Advancing Dementia Care for Rural and Hispanic Populations</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i>	0.6 months 5%	\$1,177,058 05/01/2013-04/30/2016
HHSF2232009100061 Harvard Pilgrim Health Care, Inc./FDA <i>Mini-Sentinel Prospective Observational Monitoring Program Tools (PROMPT), Rivaroxaban Surveillance (TO12)</i> Elizabeth A. Chrischilles, <i>Principal Investigator</i>	8.3%	\$54,585 07/01/2013-03/03/2016
1 R01 HL116311-01A1 NIH <i>Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care (CARE) Trial</i> Barry Carter, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Investigator</i>	0.6 months 5%	\$2,486,485 08/08/2013-07/31/2018
<i>Total Project Costs: \$3,574,806</i>		

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
Subcontract with the University of South Carolina/Patient-Centered Outcomes Research Institute <i>Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous For More Than One Outcome</i> E A. Chrischilles, <i>Investigator</i> John Brooks, <i>Principal Investigator</i> Mary Schroeder, <i>Principal Investigator</i> <i>Total Project Costs: \$270,164.62</i>	5%	\$192,975 01/01/2014-12/31/2017
FDA HHSF223200910006I FDA <i>Detection and Analysis of Adverse Events Related to Regulated Products in Automated Healthcare Data. Efforts to Develop the Sentinel Initiative. Protocol-based assessment of thromboembolic events after immunoglobulin administration - Chart Validation</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	9.8%	\$250,106 01/01/2014-03/31/2016
CDRN-1306-04631 Subcontract with University of Kansas Medical Center Research Institute, Inc/Patient-Centered Outcomes Research Institute <i>Greater Plains Collaborative Clinical Data Research Network</i> Gary Rosenthal, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i>	15%	\$1,067,713 03/06/2014-09/06/2015
R18 HL116259 NIH <i>MEDication Focused Outpatient Care for Underutilization of Secondary Prevention: MED-FOCUS</i> Barry Carter, <i>Principal Investigator</i> Elizabeth A. Chrischilles, <i>Co-Investigator</i> <i>Total Project Costs: \$9,700,587</i>	15%	\$6,801,191 04/01/2014-03/31/2019

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
R01 HS023104 <i>Stroke Prevention for Atrial Fibrillation with Multiple Chronic Conditions</i> Mary Sarrazin, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	3%	\$229,603 09/01/2014-02/28/2017
<i>Total Project Costs: \$346,700</i>		
U.S. Dept. of Health & Human Services, Centers for Disease Control & Prevention <i>Cancer Prevention and Control Research Network – Collaborating Center</i> Sue Curry, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i>	2.5%	\$4,703,139 09/30/2014-09/29/2015
<i>Total Project Costs: \$6,195,443</i>		
1 R21 HS023952-01 AHRQ <i>Design and Testing of a Mobile Cardiovascular Risk Service with Patient Partners</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	15%	\$197,410 04/01/2015-03/31/2018
<i>Total Project Costs: \$298,089</i>		
U1C RH29074 <i>Telehealth Focused Rural Health Research Center Cooperative Agreement</i> Marcia Ward, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Investigator</i>	3%	\$548,674 09/01/2015-08/31/2019
<i>Total Project Costs: \$3,337,000</i>		
CDRN-1306-04631 Subcontract with University of Kansas Medical Center Research Institute, Inc/Patient-Centered Outcomes Research Institute <i>Greater Plains Collaborative Clinical Data Research Network - PCORnet Phase II</i> Elizabeth Chrischilles, <i>Principal Investigator</i>	3.0 months	\$1,899,796 09/07/2015-12/31/2018
<i>Total Project Costs: \$2,538,880</i>		

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
R01 MD010728 Subcontract with Medical College of Wisconsin/NIH <i>Policy-relevant mechanisms of socioeconomic disparities in adherence to oral hormonal therapy for breast cancer</i> Elizabeth Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$347,194</i>	1.2 months 10%	\$187,555 08/11/2016-04/30/2020
HHSN2612013000201 NIH/NCI <i>Patient Generated Health Data (PGHD) to Enhance SEER Data Collection</i> Elizabeth Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$151,314</i>	3%	\$99,222 09/19/2016-11/01/2018
CDRN-1306-04631 Subcontract with University of Kansas Medical Center Research Institute, Inc./Patient-Centered Outcomes Research Institute, Inc. <i>Cancer Collaborative Research Group</i> E A. Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$302,870</i>	2%	\$118,186 01/01/2017-12/31/2018
KUMCRI/PCORI <i>Molecular Testing Rapid Cycle Research Project</i> Elizabeth Chrischilles, <i>Co-Principal Investigator</i> <i>Total Project Costs: \$235,215</i>	1.8 months	\$168,011 09/13/2017-09/17/2018
UL1 TR002537 NIH/NCATS <i>The University of Iowa Clinical and Translational Science Award (CTSA)</i> Patricia Winokur, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Associate Director</i> <i>Total Project Costs: \$20,605,586</i>	3.0 months	\$13,571,642 03/30/2018-02/28/2023

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
R21 HS025785 AHRQ <i>Development of a targeted portal intervention to improve depression treatment adherence, satisfaction, and outcomes</i> Elizabeth Chrischilles, <i>Co-Investigator</i> Carolyn Turvey, <i>Principal Investigator</i> <i>Total Project costs: \$299,999</i>	2%	\$196,721 07/01/2018-06/30/2020
PCRF Contract #1247 Subcontract with University of Kansas Medical Center Research Institute, Inc/Patient-Centered Outcomes Research Institute <i>GPC/PCRF PCORnet 2.0</i> Elizabeth Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$288,764</i>	15%	11/01/2018-09/30/2020
RI-CRG-1807-0002 Patient-Centered Outcomes Research Institute, Inc. <i>Development and Progression of Collaborative Research Group (CRG) Project</i> E A. Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$148,443</i>	1%	11/01/2018-11/29/2019
236165 Subcontract with Duke University/Patient-Centered Outcomes Research Institute <i>Using PCORnet to Compare Blood Pressure Control Strategies</i> Elizabeth Chrischilles, <i>Principal Investigator</i> <i>Total Project Costs: \$20,000</i>	0.5%	05/30/2019-06/30/2020
5P30CA086862-19 NIH <i>Administrative Supplement for P30 Cancer Centers Support Grants to advance rural cancer control research capacity in clinic setting</i> George Weiner, <i>Principal Investigator</i> Elizabeth Chrischilles, <i>Co-Investigator</i> <i>Total Project Costs: \$199,705</i>	2.5%	09/01/2019-08/31/2020

2. Grants Pending

Source Title P.I.	Number of Months % Effort	Direct Funds Period of Funding
-------------------------	------------------------------	-----------------------------------

D. Presentations

1. Invited Presentations

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
November 1988	Pharmacoepidemiology: A New Breed, a New Discipline	Clinical Epidemiology: State of Art" Symposium, University of Iowa, Iowa City, Iowa	Invited Lecture
March 1989	Cost-effectiveness of Pharmacotherapy	Refresher Course for the Family Physician, University of Iowa, Iowa City, Iowa	Invited Lecture
April 1989	Drug Effects in the Elderly: Harnessing Databases on Aging	Prevention '89, Atlanta, Georgia	Invited Lecture
September 1989	Biotechnology-Who will Pay?	End of Summer Science Symposium, American Pharmaceutical Association, Bethesda, Maryland	Invited Lecture
February 1990	A Cost-Benefit Assessment of Osteoporosis Therapy	Minisymposium and Etidronate Cyclical Therapy, Research Advances in Osteoporosis Second International Conference, Washington, District of Columbia	Invited Lecture
March 1990	Rationing Health Care: Biotechnology Products	American Pharmaceutical Association 137th Annual Meeting & Exhibit, American Pharmaceutical Association, Washington, District of Columbia	Invited Lecture
June 1991	Application of Epidemiologic Principles to Health Economic Research	Drug Information Association Annual Meeting, Washington, District of Columbia	Invited Lecture
1992	Myths of cost-effectiveness Analysis	Medical Student Conference, University of Iowa, Iowa City, Iowa	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
April 1992	Economic Variables in Pharmacoepidemiologic Research	Prevention '92, Baltimore, Maryland	Invited Lecture
April 1993	Avoided Inpatient Medical Costs Associated with Community Parenteral Therapy	Community Parenteral Therapy for Gram-Positive Infections: Current Applications and Future Needs, Como, Italy	Invited Lecture
September 1994	A Health Policy Model for Evaluating Interventions to Achieve Optimal Calcium Intake	An International conference on Adjuvant Nutrition and Chronic Disease: Preventive and Therapeutic Effects, Toronto, Canada	Invited Lecture
September 1994	The Cost Effectiveness of Drug Therapy in Osteoporosis	Boston Outcome Conference on Applying Patient Outcomes and Pharmacoeconomics in Pharmaceutical Care, Boston, Massachusetts	Invited Lecture
December 1994	Drug Utilization Review: The State of the Art	The Congress on Health Outcomes & Accountability, Washington, District of Columbia	Invited Lecture
1995	Iowa HCFA Demonstration Project (On-line DUR)"	40th annual Ohio Pharmaceutical Seminar, Health Outcomes and Pharmaceutical Care: Measurement, Applications, and Initiatives, Columbus, Ohio	Invited Lecture
June 1995	The Pharmacists' Intervention: Its Impact and How to Get There	4th International Symposium on Drug Development, Utilization and Costs of Medications, Montreal, Canada	Invited Lecture
October 13, 1995	Pharmacist Initiatives: Their Impact on Medication Use and Patient Outcomes	Alumni Continuing Education Meeting, University of Iowa, College of Pharmacy, Iowa City, Iowa	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
October 29, 1995	The Iowa On-line Prospective Drug Utilization Review Demonstration Project	APHA Drug Policy Study Group, American Public Health Association, San Diego, California	Invited Lecture
November 3, 1995	Issues in Evaluating Pharmaceutical Care	Research Methods Workshop: Evaluation of Outcomes of Pharmaceutical Care, Canadian Pharmaceutical Association, Toronto, Canada	Invited Lecture
March 1996	Federally Sponsored Pharmaceutical Outcomes Demonstration Projects: An Update	American Pharmaceutical Association 1996 Annual Meeting and Exposition, American Pharmaceutical Association, Nashville, Tennessee	Invited Lecture
April 1996	How Does a Medical Assistance Agency Measure the Impact of a Pharmacy Benefit?	Changing Healthcare and Changing Rules--A Profession in Transition, Third Annual Glaxo Wellcome Conference for Pharmacy Faculty, Durham, North Carolina	Invited Lecture
November 1997	Assessing the Quality of Pharmaceutical Care Initiative: The Iowa Experience	Providing Pharmaceutical Services to the Medicaid Population: A Forum on Public Policy and Quality Assessment, Council of Ohio Colleges of Pharmacy, Columbus, Ohio	Invited Lecture
April 1998	Dollars and Sense: Practical Guide to Cost Analysis	Society for Healthcare Epidemiology of America, 8th Annual Meeting, Society for Healthcare Epidemiology of America, Orlando, Florida	Invited Lecture
2000	Prostate Cancer Project	University of Iowa Cancer Center, Iowa City, Iowa	Invited Lecture
January 2000	Prevention of Secondary Conditions	Blue Ribbon Panel, Iowa City, Iowa	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
March 2000	Initiation of prostate non-selective alpha antagonists and hypotension – related events among men with benign prostatic hyperplasia (BPH) in a large Medigap plan	URO2000, Cancun, Mexico	Invited Lecture
June 2000	Elements of an Ideal DUR System	CoE Orientation Meeting, Bethesda, Maryland	Invited Lecture
October 28, 2000	Rural Childhood Asthma Study	Texas Scientific Symposium, Austin, Texas	Invited Lecture
April 27, 2001	Initiation of prostate non-selective alpha antagonists and hypotension – related events among men with benign prostatic hyperplasia (BPH) in a large Medigap plan: Part 2	URO2001 Speaker’s Meeting, Santa Barbara, California	Invited Lecture
June 24, 2004	Evidence-Based Drug-Drug Interaction Criteria for Computer Systems	U.S. Pharmacopoeia, Carefree, Arizona	Invited Lecture
April 13, 2005	Pharmacy Information Systems Technologies for Enhancing Medication Safety	Institute of Medicine Committee on Identifying and Preventing Medication Errors, Institute of Medicine, Washington, District of Columbia	Invited Lecture
September 2005	Pilot Projects Using the Shared Resources of the Database Core	Integrating Aging and Cancer Research in NCI Cancer Centers, 2nd Annual Meeting of NCI/NIA P20 Grant Awardees, NCI/NIA, Bethesda, Maryland	Invited Lecture
September 19, 2006	Improving Safety and Effectiveness of Medication Use Among Older Adults	CMS Evidence Forum, Baltimore, Maryland	Invited Lecture
August 28, 2007	The Quest for Rational Therapeutics	Distinguished Faculty Lecture, University of Iowa, College of Public Health, Iowa City, Iowa	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
September 2007	Personal Health Records and Patient-Centered Medication Therapy Management	AHRQ 2007 Annual Meeting, AHRQ, Bethesda, Maryland	Invited Lecture
March 26, 2008	Aging and lymphoma therapeutics: Translating evidence into practice	Southern Illinois University, Springfield, Illinois	Invited Lecture
September 2008	PHRs for Medication Use: Views from Elders and Their Physicians	AHRQ 2008 Annual Meeting, AHRQ, Bethesda, Maryland	Invited Lecture
November 18, 2008	The Quest for Rational Therapeutics	University of Kansas Medical Center	Invited Lecture
March 2009	Medication Use Quality Among Older Adults	AHRQ Steering Committee meeting, AHRQ, Rockville, Maryland	Invited Lecture
April 2009	Pharmaceutical Case Management and Living Well with a Disability	2009 CDC State Disability and Health Grantees, Researchers, and Partners Annual Meeting, CDC, New Orleans, Louisiana	Invited Lecture
June 3, 2009	Iowa Experience with Medication Therapy Management Precursor Programs	CMS, Baltimore, Maryland	Invited Lecture
June 3, 2009	Measuring Prescribing Quality	CMS, Baltimore, Maryland	Invited Lecture
June 9, 2009	Healthcare reform and medication therapy management for rural and underinsured	Congressional briefing	Invited Lecture
April 2010	Cancer Care for Older Adults: Disparity or Clinical Reality	University of Alabama at Birmingham	Invited Lecture
June 2010	Pharmacoepidemiology	Midwest CTSA Consortium: Rural Health and Health Disparities Research in the Heartland, University of Kansas Medical Center School of Nursing	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
July 30, 2010	Comparative Effectiveness Research Opportunities	Midwest Social & Administrative Pharmacy Conference, Iowa City, Iowa	Invited Lecture
September 30, 2010	Medication Management & Medicare Beneficiaries: Best Practices and Policy Directions	Rebalancing Healthcare in the Heartland 4 Conference, Des Moines, Iowa	Invited Lecture
March 8, 2011	Expert panel discussion on Comparative Effectiveness Research	University of Iowa, College of Nursing	Invited Lecture
March 30, 2011	Putting the Patient Back in Patient Centered Care (2) Presentation: Personal Health Records and Elder Medication Use Quality	AHRQ Webinar, AHRQ	Invited Lecture
November 26, 2012	IOM Large Simple Trials in Learning Health Care Systems (Chrischilles EA)	Panel presentation, IOM, Washington, District of Columbia	Invited Lecture
January 31, 2013	Presentation on protocol core activities (Chrischilles EA)	Fifth Annual Sentinel Initiative Public Workshop, Washington, District of Columbia	Invited Lecture
July 25, 2013	“Mini-Sentinel PROMPT: Prospective Routine Observational Monitoring Program Tools (Chrischilles E)	Kaiser Permanente Mini-Sentinel Investigator’s meeting	Invited Lecture
August 1, 2013	Postmarket Considerations to Promote Safe Use and Continued Evidence Development of Special Medical Use Products (McClellan (Moderator) M, Boutin M, Califf R, Chrischilles E, Bullman R, Pinto P)	Brookings expert workshop on Limited Use for Drugs Developed in an Expedited Manner to Meet an Unmet Medical Need, Washington, District of Columbia	Invited Lecture
September 16, 2013	Invited presentation: “An Overview of the Design and Implementation of FDA’s Prospective Routine Observational Monitoring Program Tools (PROMPT) for Safety Surveillance (Chrischilles EA, Nelson J)	Webinar: Brookings Roundtable on Active Medical Product Surveillance	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
January 14, 2014	Invitation to serve as a panelist, "Development of Prospective Routing Observational Monitoring Program Tools (PROMPT) for medical product surveillance" (Chrischilles EA)	Annual Sentinel Initiative Public Workshop, Washington, District of Columbia	Invited Lecture
April 14, 2014	Invited Presentation: Population Database Studies of Cancer Treatment Benefit: Nicety or Necessity	Cancer Center Grand Rounds, Med Alumni Auditorium, E331 GH	Invited Lecture
July 8, 2014	Invited Presentation: Successful aging in place for adults in rural communities	Iowa Farm Bureau Federation Foundation, S162 College of Public Health Building	Invited Lecture
October 16, 2014	"Update on FDA's Query Tools System (including the PROMPT component)" (Shoaibi A, Chrischilles E)	IMEDS community call	Invited Lecture
August 24, 2015	Abstract presentation: Safety Surveillance of New Oral Anticoagulants Within the Mini-Sentinel Program Progress, Challenges and Future Directions	ISPE 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)	Invited Lecture
November 20, 2015	Invited remote presentation: How the Share Thoughts on Care Study found better health through survivorship planning (Chrischilles E, McDowell B)	Canadian Survivorship Research Consortium Rounds	Invited Lecture
December 10, 2015	Invited to workshop panel discussion, Data Quality and Missing Data in Patient-Centered Outcomes Research Using EMR/Claims Data (Chrischilles E)	PCORI workgroup meeting	Invited Lecture
July 12, 2016	Prospective Surveillance Pilot of Rivaroxaban Safety Within the US Food and Drug Administration Sentinel Program (Chrischilles E)	OSE/DEPI WebEx presentation	Invited Lecture

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
July 25, 2016	Engaging Special Populations: Lessons Learned	Patient Engagement Symposium: A New Frontier for Clinical Research, Institute for Clinical & Translational Science	Invited Lecture
July 9, 2018	Invited:Panel Presentation for conference: Establishing a framework to operationalize and validate real-world data sets	Washington, DC, District of Columbia	Invited Lecture
September 25, 2018	Invited Presentation: NIA Multimorbidity Workshop	Bethesda, Maryland	Invited Lecture
February 6, 2019	Establishing common variables needed to identify patient populations, exposure variables, and confounding factors	Friends of Cancer Research, Washington, DC, District of Columbia	Invited Lecture
May 14, 2019	Measuring Multimorbidity: matching the instrument and the purpose	College of Nursing Research Forum, The University of Iowa	Invited Lecture
September 21, 2019	Collaborative cancer outcomes research opportunities in PCORnet and the PCORnet common data model	Big Ten Cancer Research Consortium Annual Summit, Chicago, Illinois	Invited Lecture
January 30, 2020	PCORnet, the GPC, and Networked Research Opportunities and Challenges (Chrischilles E)	CTSA collaboration, University of Nebraska Medical Center, Omaha	Invited Lecture
February 5, 2020	Invited abstract presentation, "Exploring Real-World Data for Assessing and Mitigating Cardio-oncology Outcomes of Radiation Therapy (Chrischilles E, O'Rorke M, McDowell B, Spitz D, Allen B, London B, Grumbach I)	HCCC FRMI/CEPS dinner symposium, The University of Iowa, Iowa City, Iowa	Invited Lecture

2. Conference Presentations/Posters

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
-------------	--------------	---------------------	--------------------------

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
March 1996	Pharmacist-Pharmacist: Continuity of Care	American Pharmaceutical Association 1996 Annual Meeting and Exposition, Nashville, Tennessee	Oral
November 1996	Pharmacists' Cognitive Services in an On-Line Drug Use Review (UPDUR) System in Iowa	Empowering the Disadvantaged, American Public Health Association 124th Annual Meeting and Exposition, New York, New York	Oral
April 2000	Nonselective Alpha Blocker Medication Patterns in Pension Plan Health Claims Data	American Urological Association	Oral
October 2000	Rural Childhood Asthma Study	EJ/CBPIR Grantee Meeting, Seattle, Washington	Oral
November 2000	Rural Childhood Asthma Study	128th APHA Annual Meeting and Exposition, American Public Health Association, Boston, Massachusetts	Oral
November 2002	Childhood Asthma in a Rural Iowa Population	American Public Health Association Annual Meeting, American Public Health Association, Philadelphia, Pennsylvania	Oral
November 2002	Mobility Limitations and Secondary Conditions Among Adult Medicare Beneficiaries	American Public Health Association Annual Meeting, American Public Health Association, Philadelphia, Pennsylvania	Oral
May 2003	Effect of Clinical Factors on Neutropenia-Related Inpatient Charges Among Newly Diagnosed Non-Hodgkins Lymphoma (NHL) During First Course Chemotherapy	American Society of Clinical Oncology, Chicago, Illinois	Oral

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
May 2003	Time to First Neutropenia Hospitalization During Chemotherapy for Non-Hodgkin's Lymphoma: an Iowa SEER-Medicare Study	American Society of Clinical Oncology, Chicago, Illinois	Oral
October 2004	A longitudinal study of atypical antipsychotic prescribing patterns in the Iowa Medicaid population (Abstract No. 295E)	American College of Pharmacy annual meeting, American College of Pharmacy, Dallas, Texas	Poster
May 2005	An Algorithm for Identifying a Population-Based Sample of Children with Frequent Asthma Symptoms	Proceedings of the American Thoracic Society, American Thoracic Society, San Diego, California	Oral
May 2005	Indoor Surface and Airborne Concentrations of Endotoxin and $\beta(1-3,1-6)$ -Glucans in the Homes of Rural Asthmatic Children	Proceedings of the American Thoracic Society, American Thoracic Society, San Diego, California	Oral
March 2006	Estimating the Effectiveness of Early-stage Lung Cancer Adjuvant Treatments in Practice Using Instrumental Variable Methods (Brooks JM, Chrischilles EA, Chen-Hardee S, Cho E, Scott S)	CERTs/PATHs meeting, Washington, District of Columbia	Poster
November 2007	Risk Factors for Adverse Drug Events in Older Adults with Mobility Limitations	GSA 60th Annual Scientific Meeting, GSA, San Francisco, California	Oral
June 2008	Iowa CERT Medication Therapy Management Products	CERT meeting, CERT, Rockville, Maryland	Oral
January 14, 2009	Observational Research Design	Co-Sponsored by the American Association of Colleges of Pharmacy and the International Society of Pharmacoeconomics and Outcomes Research	Oral

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
April 2009	Living Well with a Disability and Collaborative Medication Management (Zander K, Gryzlak BM, Chrischilles EA, Lindgren S, Doucette W, Farris K, Degarmo K, Rubenstein L, Wallace RB)	2009 CDC State Disability and Health Grantees, Researchers, and Partners Annual Meeting, CDC, New Orleans, Louisiana	Poster
April 2010	Relation of symptom experience with anticholinergic drug exposure in older veterans. (Carnahan RM, Lund BC, Chrischilles EA, Kaboli PJ)	College of Psychiatric and Neurologic Pharmacists annual meeting, College of Psychiatric and Neurologic Pharmacists, San Antonio, Texas	Poster
July 28, 2010	Comparative Effectiveness Research Opportunities	Midwest Pharmacy Meeting, Iowa City, Iowa	Oral
February 2011	Enhanced Data to Accelerate Complex Patient Comparative Effectiveness Research	AHRQ Complex Patient Research Learning Network Meeting, AHRQ, Rockville, Maryland	Poster
September 9, 2012	Enhanced Data to Accelerate Complex Patient Comparative Effectiveness Research (Chrischilles EA, Schneider K, O'Donnell BE, Letuchy EM, Wright KB, Lessman G, Lund BC, Gryzlak BM, Wilwert J, Robinson JG)	AHRQ Multiple Chronic Conditions Research Network meeting, Bethesda, Maryland	Poster
2013	Foundations of Clinical Practice II: Evidence-Based Clinical Practice	The University of Iowa	Oral
May 19, 2014	Implementation of a physician/pharmacist model to improve blood pressure control in a diverse population. (Carter B, Coffey CS, Ardery G, Ecklund D, James PA, Egan BM, Vander Weg M, Chrischilles E)	American Society of Hypertension Annual Meeting, New York, New York	Poster

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
March 2015	LCIS, race and age: 10-year cancer specific survival after a diagnosis of lobular in situ disease (Lizarraga I, Schroeder MC, Sugg S, Chrischilles EA, Weigel R, Thomas A)	SSO Annual Cancer Symposium, Society of Surgical Oncology	Poster
August 30, 2017	Prospective Surveillance Pilot of Rivaroxaban Safety within the US Food and Drug Administration Sentinel System (Chrischilles EA)	33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada	Oral
September 18, 2019	Using PCORnetR to Understand Use of Molecular Tests and Treatments for Cancerous Tumors (Chrischilles E, Carnahan R, Waitman R, on behalf of the Molecular Testing Rapid Cycle Project Team)	2019 PCORI Annual meeting, Washington, DC, District of Columbia	Poster

3. Other Presentations

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
1986	Weekly Epidemiology Seminar – Epidemiology Division	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa	Seminar
1992	Weekly Aging Epidemiology Seminar – Epidemiology Division	Department of Preventive Medicine, College of Medicine, University of Iowa	Seminar
1993	Weekly Critique of Literature	Division of General Medicine, Clinical Epidemiology and Health Services Research, College of Medicine, University of Iowa	Seminar
November 1994	What are the necessary and desirable attributes of the research infrastructure for studying patient outcomes of pharmaceutical care interventions?	Patient Outcomes of Pharmaceutical Interventions, American Pharmaceutical Association, Washington, District of Columbia	Paper

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
2000	Essential Services	IDPH/CPH Seminar Series	Seminar
2007	UI Older Adults Center for Education and Research on Therapeutics (CERT)	VA Medical Center, Iowa City, Iowa	Seminar
May 1, 2008	Population Sciences and the Holden Comprehensive Cancer Center	Department of Community and Behavioral Health, College of Public Health, University of Iowa	Seminar
February 2009	Research Opportunities in Pharmacy Quality. Speaker: Manager of Research Strategies for Competitive Health Analytics at Humana, David Nau	Iowa CERT	Seminar
February 17, 2009	Observational Designs for Practice-Relevant Medication Use Research	Master of Public Health Program, College of Public Health, University of Iowa	Seminar
March 2009	Discussion on the Outcomes medication therapy management program and pharmacist network. Speaker: Vice President of Outcomes Pharmaceutical Health Care, Brand Newland	Iowa CERT	Seminar
July 2010	Discussion on drug safety surveillance methodology research opportunities. Speaker: Dr. Jennifer Nelson, Associate Investigator and Head of the Biostatistics Unit at Group Health Research Institute (GHRI)	Iowa CERT	Seminar
2011	Debating the RCT vs Observational Study for CER	University of Iowa Comparative Effectiveness Research (CER) Seminar Series	Seminar
March 17, 2013	Epi Seminar, "Nighttime Dosing of Anti-Hypertensive Medications: A Pragmatic Clinical Trial"	University of Iowa, N120 CPHB	Seminar

<u>Year</u>	<u>Title</u>	<u>Organization</u>	<u>Presentation Type</u>
December 5, 2016	How HCCC can do patient-centered outcomes research that is 90 million strong: the promise of PCORnet	HCCC Grand Rounds	Grand Rounds
October 11, 2017	Invited workshop: NCI Healthcare Delivery PQ workshop	Bethesda, Maryland	Workshop
March 2, 2018	Invited workshop: American Cancer Society Roundtable	Washington, DC, District of Columbia	Workshop

III. SERVICE

A. Offices/appointments held in professional organizations

1. Editorships

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1990-1998	Editorial Board, DICP, Annals of Pharmacotherapy	
2012-2013	Editorial Advisory Board, American Journal of Geriatric Pharmacotherapy (AJGP)	Editorial Board

2. Review Panels

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2006	Special Emphasis Panel to review DeCIDE grants (Agency for Healthcare Research and Quality)	Reviewer, Grant Proposals
2008-2014	Health Services Organization and Delivery (HSOD) Study Section (NIH), NIH	Reviewer, Grant Proposals
2015	Special Emphasis Panel grant reviews (NIH)	Reviewer, Grant Proposals

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2017	Reviewer, Greater Plains Collaborative (GPC) Clinical Data Research Network Inter-Institutional Pilot Grant Program, PCORI/PCORnet Network – CDRN-1306-04631. Served as reviewer for inaugural pilot grant program focused on optimizing usage of the GPC's data infrastructure, inter-institutional collaboration and patient engagement.	Reviewer
2018-2019	Special Emphasis Panel grant reviews (NCI)	Reviewer, Grant Proposals

3. Professional Organizations (state and/or national)

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1979-Present	American Society of Hospital Pharmacists	Member
1979-Present	Iowa Pharmacists Association	Member
1988-2000	American College of Clinical Pharmacy	Member
1989-Present	American Public Health Association	Member
1989-Present	Society for Epidemiologic Research	Member
1989-2001	International Society for Pharmacoepidemiology	Member
1989-2000	Drug Information Association	Member
1993-Present	American Pharmaceutical Association	Member
2004-Present	American Society of Clinical Oncology	Member
2015-Present	International Society for Pharmacoepidemiology	Member
2019-Present	American College of Epidemiology	Member
2019-Present	American Heart Association	Member

B. Other Professional Service

1. Referee Manuscripts/Journal Reviews

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1986-Present	American Journal of Health Systems Pharmacy	Reviewer, Publications
1986-Present	Annals of Pharmacotherapy	Reviewer, Publications
1986-Present	Journal of Gerontology	Reviewer, Publications
1986-Present	Journal of the American Geriatrics Association	Reviewer, Publications
1986-Present	Journal of the American Medical Informatics Association	Reviewer, Publications
1986-Present	Journal of the American Pharmacists Association	Reviewer, Publications
1986-Present	Pharmacoepidemiology and Drug Safety	Reviewer, Publications

2. Organize Conference, Paper Session, etc.

<u>Year</u>	<u>Organization</u>	<u>Position</u>
-------------	---------------------	-----------------

3. State Committees

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1984-1986	Task Force Committee to revise the Iowa Pharmacy Practice Act, Iowa Pharmacists Association	Member
1998-2001	Committee to evaluate the Iowa Medicaid Prior Authorization and Pro DUR programs	Member
2008-2009	Task Force on Health and Long-Term Care Access, Iowa Department of Public Health	Advisory Council Member

4. National Committees

<u>Year</u>	<u>Organization</u>	<u>Position</u>
-------------	---------------------	-----------------

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1986-1990	Medications Data Committee for Established Populations for Epidemiologic Studies on the Elderly (National Institute on Aging)	Member
1988-1989	Task Force on the Cost-Effectiveness of Pharmaceuticals and Pharmacy Services (American Pharmaceutical Association, Pharmaceutical Manufacturers Association, American Association of Clinical Pharmacy)	Member
1991	Panel to Design HCFA Demonstration Project on Cost-Effectiveness of Prospective On-line Drug Utilization Review and Pharmacists' Cognitive Services (Health Care Financing Administration)	Member
1992	Workshop on Cost-Effective Strategies for Osteoporosis (National Institutes of Health / Agency for Health Care Policy and Research)	Attendee
1994	NIH Consensus Development Conference on Optimal Calcium Intake (National Institutes of Health)	Expert Panel
1995-2000	Drug Utilization Review Advisory Board (U.S. Pharmacopoeia)	Member
1997-1998	Therapies of Choice Drug Utilization Review prototype in congestive heart failure, Work-group Chair (U.S. Pharmacopoeia)	Chair
1998-2001	Studies of Clinically Relevant Indicators for Pharmacologic Therapy (Health Care Financing Administration)	Scientific Advisor

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1998-1999	Prospective Drug Utilization Review Policy Conference Steering Committee Chair (US Pharmacopoeia and American Pharmacists Association)	Chair
2000-2005	Therapeutic Decision Making Expert Committee (U.S. Pharmacopoeia)	Chair
2006-2012	Centers for Education and Research on Therapeutics Steering Committee (Agency for Healthcare Research and Quality)	Member
2006-2007	Research, Education and Practice Committee, Gerontological Society of America	Clinical Medicine Section Representative
2007	Pharmacovigilance Think Tank (US Food and Drug Administration)	Expert Panel
2009-2015	Mini-Sentinel Protocol Core (US Food and Drug Administration)	Co-Lead
2009	Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation (National Cancer Institute)	Attendee
2009	Drug-Drug Interaction Conference Planning Committee (Agency for Healthcare Research and Quality)	Member
2009	Sentinel Methods Think Tank, Brookings Institution	Expert Panel
2009	Technical Expert Workshop: Furthering the Design of Consumer Health Information Technology (Agency for Healthcare Research and Quality)	Expert Panel

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2014	Informed Stakeholder Deliberative Engagement Meeting, Center for Medical Technology Policy (CMTP), in collaboration with the Johns Hopkins Berman Institute of Bioethics, Johns Hopkins Community Physicians, and Geisinger Health System, Baltimore, MD	Attendee
2014	Network Research Methods Work Group: handling missing and inconsistent data in data networks (Patient-Centered Outcomes Research Institute)	Member
2015-Present	Advisory Panel on Clinical Trials post-award expert subcommittee (Patient-Centered Outcomes Research Institute)	Member
2015-Present	Sentinel Initiative Applied Surveillance Core (US Food and Drug Administration)	Co-Lead
2019-Present	Endocrinologic and Metabolic Advisory Committee (EMDAC)	Member

5. Professionally Relevant Community Involvement

<u>Year</u>	<u>Organization</u>	<u>Position</u>
-------------	---------------------	-----------------

6. Professional Consulting

<u>Year</u>	<u>Organization</u>	<u>Position</u>
-------------	---------------------	-----------------

7. Other

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2007	Developing program on rural medication therapy management, University of Pittsburgh, College of Pharmacy	Reviewer
2019	Presentation: Holden Comprehensive Cancer Center, Research Executive Committee, The University of Iowa	Community Outreach and Engagement

C. Departmental, Collegiate or University Service

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1987-1989	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Graduate Admissions Committee	Member
1990-1992	University of Iowa, Council on the Status of Women	Member
1990-1992	Council on the Status of Women, University of Iowa, Subcommittee on parenting and childcare issues	Member
1990-1991	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Curriculum Committee	Member
1990	Department of Preventive Medicine, College of Medicine, University of Iowa, Division subcommittee on M.S. epidemiology curriculum	Member
1991-1997	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, M.S. Final Examination Committee	Member
1991-1994	Department of Preventive Medicine, College of Medicine, University of Iowa, Department Master's Final Exam Committee	Member
1995-Present	Department of Epidemiology, University of Iowa, Department Graduate Admissions Committee	Member
1995-1996	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Curriculum Committee	Member
1995-1996	Department of Preventive Medicine, College of Medicine, University of Iowa, Department Curriculum Committee	Member

<u>Year</u>	<u>Organization</u>	<u>Position</u>
1995-1996	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Graduate Admissions Committee	Member
1996-1997	Department of Preventive Medicine, College of Medicine, University of Iowa, Teaching Evaluation & Exam Policy Oversight Committee	Member
1997-1998	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Continuing Education & Seminar Committee	Member
1997-1998	Department of Preventive Medicine and Environmental Health, College of Medicine, University of Iowa, Graduate Admissions & Training Committee	Member
1998-2006	University of Iowa, Institutional Review Board-Committee A	Member
1998-2000	College of Public Health, University of Iowa, Graduate Admissions Committee	Member
2000-Present	Department of Epidemiology, College of Public Health, University of Iowa, Departmental MS Admissions Committee	Member
2000-2010	Department of Epidemiology, College of Public Health, University of Iowa, Departmental MPH Admissions Committee	Chair
2000-2010	Department of Epidemiology, College of Public Health, University of Iowa, Departmental Plan of Study Committee	Chair
2000-2010	Department of Epidemiology, College of Public Health, University of Iowa, Executive Committee	Member

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2000-2002	College of Public Health, University of Iowa, MPH Committee	Member
2005-2006	College of Public Health, University of Iowa, MPH Advisory Committee	Member
2006-2007	University of Iowa, Presidential Search Committee	Member
2007-Present	University of Iowa Holden Comprehensive Cancer Center, Associate Director Population Sciences	Associate Director
2007-Present	Holden Comprehensive Cancer Center, Executive Committee	Member
2007-Present	Holden Comprehensive Cancer Center	Member
2007-2008	Department of Epidemiology, College of Public Health, University of Iowa, Departmental Consulting Group for Promotion and Tenure	Chair
2007-2008	College of Public Health, University of Iowa, Search Committee for the Endowed Chair in Rural Safety and Health for OEH	Member
2008-2009	College of Pharmacy, University of Iowa, Departmental Consulting Group	Member
2009-Present	University of Iowa, MSTP Admissions Committee	Member
2009-2015	Holden Comprehensive Cancer Center, Population Research Core	Co-Director
2009	Department of Community and Behavioral Health, College of Public Health, University of Iowa, Departmental Consulting Group	Member
2010-2011	College of Pharmacy, University of Iowa, HSR Faculty Search Committee	Member

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2011-2014	College of Public Health, University of Iowa, CPH Research Council	Member
2011-2012	Department of Epidemiology, College of Public Health, University of Iowa, Departmental Consulting Group for Promotion and Tenure	Chair
2012	University of Iowa, Search Committee for Division of Sponsored Programs Director	Member
2014-Present	Department of Epidemiology, The University of Iowa, MS in Clinical Investigations Admissions	Member
2014-2016	Department of Epidemiology, The University of Iowa, PhD Qualifying Exam	Member
2014-2016	Department of Epidemiology, The University of Iowa, Teaching Evaluation	Member
2014-2015	Department of Epidemiology, College of Public Health, University of Iowa, Departmental MPH Admissions Review	Member
2014-2015	OVPR Search Committee for AVP Compliance	Member
2014	CPH Associate Dean for Administration Search Committee	Member
2015-Present	ICTS Management Committee	Member
2016-2017	Cancer Molecular Epidemiologist Search Committee	Chair
2016	Review of the UI Interdisciplinary Graduate Program in Informatics	Member
2017-Present	College of Public Health Executive Committee	Member
2018	Department of Community & Behavioral Health, DEO Search Committee	Member

<u>Year</u>	<u>Organization</u>	<u>Position</u>
2018	Dept. of Epidemiology, MS Final Exam Committee	Member